US20070184072A1 - Multivalent pneumococcal polysaccharide-protein conjugate composition - Google Patents

Multivalent pneumococcal polysaccharide-protein conjugate composition Download PDF

Info

Publication number
US20070184072A1
US20070184072A1 US11/644,207 US64420706A US2007184072A1 US 20070184072 A1 US20070184072 A1 US 20070184072A1 US 64420706 A US64420706 A US 64420706A US 2007184072 A1 US2007184072 A1 US 2007184072A1
Authority
US
United States
Prior art keywords
polysaccharide
serotype
carrier protein
conjugate
reacting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/644,207
Other languages
English (en)
Inventor
William Hausdorff
George Siber
Peter Paradiso
A. Prasad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39386416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20070184072(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/395,593 external-priority patent/US20060228380A1/en
Application filed by Wyeth LLC filed Critical Wyeth LLC
Priority to US11/644,207 priority Critical patent/US20070184072A1/en
Assigned to WYETH reassignment WYETH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PRASAD, A. KRISHNA, PARADISO, PETER R., SIBER, GEORGE RAINER, HAUSDORFF, WILLIAM P.
Publication of US20070184072A1 publication Critical patent/US20070184072A1/en
Priority to CNA2007800515966A priority patent/CN101610788A/zh
Priority to JP2009543058A priority patent/JP5815207B2/ja
Priority to PT78654654T priority patent/PT2094304E/pt
Priority to RU2009123449/15A priority patent/RU2484846C2/ru
Priority to KR1020157031392A priority patent/KR20150129052A/ko
Priority to BRPI0721136A priority patent/BRPI0721136B8/pt
Priority to SG2011089216A priority patent/SG177174A1/en
Priority to PCT/US2007/086976 priority patent/WO2008079653A1/en
Priority to DK07865465.4T priority patent/DK2094304T3/en
Priority to AU2007337214A priority patent/AU2007337214B9/en
Priority to HUE07865465A priority patent/HUE028421T2/en
Priority to ES07865465.4T priority patent/ES2559060T3/es
Priority to EP07865465.4A priority patent/EP2094304B1/en
Priority to PL07865465T priority patent/PL2094304T3/pl
Priority to MX2009006548A priority patent/MX336934B/es
Priority to KR1020097015487A priority patent/KR101511393B1/ko
Priority to CA2673558A priority patent/CA2673558C/en
Priority to CN201510490666.4A priority patent/CN105079800A/zh
Priority to KR1020147029398A priority patent/KR20140130564A/ko
Priority to SI200731710T priority patent/SI2094304T1/sl
Priority to CL2007003781A priority patent/CL2007003781A1/es
Priority to US12/471,113 priority patent/US20090234108A1/en
Priority to IL199324A priority patent/IL199324A/en
Priority to ZA200904619A priority patent/ZA200904619B/xx
Priority to US12/887,636 priority patent/US8895724B2/en
Assigned to WYETH LLC reassignment WYETH LLC CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: WYETH
Priority to JP2013241484A priority patent/JP2014065721A/ja
Priority to US14/520,108 priority patent/US9480736B2/en
Priority to HK16103260.9A priority patent/HK1215189A1/zh
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Definitions

  • the present invention relates generally to the field of medicine, and specifically to microbiology, immunology, vaccines and the prevention of infection by a bacterial pathogen by immunization.
  • Streptococcus pneumoniae is a leading cause of meningitis, pneumonia, and severe invasive disease in infants and young children throughout the world.
  • the multivalent pneumococcal polysaccharide vaccines have been licensed for many years and have proved valuable in preventing pneumococcal disease in elderly adults and high-risk patients.
  • infants and young children respond poorly to most pneumococcal polysaccharides.
  • the 7-valent pneumococcal conjugate vaccine (7vPnC, Prevnar®) was the first of its kind demonstrated to be highly immunogenic and effective against invasive disease and otitis media in infants and young children. This vaccine is now approved in many countries around the world.
  • Prevnar contains the capsular polysaccharides from serotypes 4, 6B, 9V, 14, 18C, 19F and 23F, each conjugated to a carrier protein designated CRM 197 .
  • Prevnar covers approximately 80-90%, 60-80%, and 40-80% of invasive pneumococcal disease (IPD) in the US, Europe, and other regions of the world, respectively [1,2].
  • IPD invasive pneumococcal disease
  • Surveillance data gathered in the years following Prevnar's introduction has clearly demonstrated a reduction of invasive pneumococcal disease in US infants as expected ( FIG. 1 ) [3,4].
  • serotypes 6A and 19A are associated with high rates of antibiotic resistance ( FIG. 2 ) [7,8,9]. While it is possible that serogroup cross-protection will result in a decline of serotype 6A and 19A disease as more children are immunized, there is evidence to suggest that there will be a limit to the decline, and a significant burden of disease due to these serotypes will remain (see below).
  • the present invention provides generally a multivalent immunogenic composition
  • a multivalent immunogenic composition comprising 13 distinct polysaccharide-protein conjugates, wherein each of the conjugates contains a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to a carrier protein, together with a physiologically acceptable vehicle.
  • an adjuvant such as an aluminum-based adjuvant, is included in the formulation.
  • the present invention provides a 13-valent pneumococcal conjugate (13vPnC) composition comprising the seven serotypes in the 7vPnC vaccine (4, 6B, 9V, 14, 18C, 19F and 23F) plus six additional serotypes (1, 3, 5, 6A, 7F and 19A).
  • the present invention also provides a multivalent immunogenic composition, wherein the capsular polysaccharides are from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F of Streptococcus pneumoniae and the carrier protein is CRM 197 .
  • the present invention further provides a multivalent immunogenic composition, wherein the capsular polysaccharides are from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9v, 14, 18C, 19A, 19F and 23F of Streptococcus pneumoniae , the carrier protein is CRM 197 , and the adjuvant is an aluminum-based adjuvant, such as aluminum phosphate, aluminum sulfate and aluminum hydroxide. In a particular embodiment of the invention, the adjuvant is aluminum phosphate.
  • the present invention also provides a multivalent immunogenic composition, comprising polysaccharide-protein conjugates together with a physiologically acceptable vehicle, wherein each of the conjugates comprises a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to a carrier protein, and the capsular polysaccharides are prepared from serotype 3 and at least one additional serotype.
  • the additional serotype is selected from the group consisting of serotypes 1, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.
  • the carrier protein is CRM 197 .
  • the composition comprises an adjuvant, such as an aluminum-based adjuvant selected from aluminum phosphate, aluminum sulfate and aluminum hydroxide. In a particular embodiment, the adjuvant is aluminum phosphate.
  • the present invention also provides a multivalent immunogenic composition, comprising polysaccharide-protein conjugates together with a physiologically acceptable vehicle, wherein each of the conjugates comprises a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to a carrier protein, and the capsular polysaccharides are prepared from serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and at least one additional serotype.
  • the additional serotype is selected from the group consisting of serotypes 1, 3, 5, 6A, 7F, and 19A.
  • the carrier protein is CRM 197 .
  • the composition comprises an adjuvant, such as an aluminum-based adjuvant selected from aluminum phosphate, aluminum sulfate and aluminum hydroxide.
  • the adjuvant is aluminum phosphate.
  • the present invention also provides a method of inducing an immune response to a Streptococcus pneumoniae capsular polysaccharide conjugate, comprising administering to a human an immunologically effective amount of any of the immunogenic compositions just described.
  • any of the immunogenic compositions administered is a single 0.5 mL dose formulated to contain: 2 ⁇ g of each saccharide, except for 6B at 4 ⁇ g; approximately 29 ⁇ g CRM 197 carrier protein; 0.125 mg of elemental aluminum (0.5 mg aluminum phosphate) adjuvant; and sodium chloride and sodium succinate buffer as excipients.
  • the method comprises (i) reacting purified Pn 1 polysaccharide with an alkaline pH buffer resulting in a partially de-O-acetylated Pn 1 polysaccharide; (ii) reacting the partially de-O-acetylated Pn 1 polysaccharide with a mild acid resulting in a neutralized, partially de-O-acetylated Pn 1 polysaccharide; (iii) reacting the neutralized, partially de-O-acetylated Pn 1 polysaccharide with an oxidizing agent resulting in an activated Pn 1 polysaccharide; (iv) compounding the activated Pn 1 polysaccharide with a carrier protein; (v) reacting the compounded, activated Pn 1 polysaccharide and carrier protein with a
  • the method comprises (i) reacting purified Pn 1 polysaccharide with a bicarbonate/carbonate buffer resulting in a partially de-O-acetylated Pn 1 polysaccharide; (ii) reacting the partially de-O-acetylated Pn 1 polysaccharide with acetic acid resulting in a neutralized, partially de-O-acetylated Pn 1 polysaccharide; (iii) reacting the neutralized, partially de-O-acetylated Pn 1 polysaccharide with sodium periodate resulting in an activated Pn 1 polysaccharide; (iv) purifying the activated Pn 1 polysaccharide; (v) compounding the activated Pn 1 polysaccharide with a carrier protein; (vi) co-lyophilizing the compounded, activated Pn 1 polysaccharide and carrier protein; (vii) reacting the co-lyophilized, activated Pn 1 polysaccharide and carrier protein
  • a method for making an activated Streptococcus pneumoniae Pn 1 polysaccharide comprises (i) reacting purified Pn 1 polysaccharide with an alkaline pH buffer resulting in a partially de-O-acetylated Pn 1 polysaccharide; (ii) reacting the partially de-O-acetylated Pn 1 polysaccharide with a mild acid resulting in a neutralized, partially de-O-acetylated Pn 1 polysaccharide; and (iii) reacting the neutralized, partially de-O-acetylated Pn 1 polysaccharide with an oxidizing agent resulting in an activated Pn 1 polysaccharide.
  • FIG. 1 depicts the changes in IPD rates by serotype in US children ⁇ 2 years of age from baseline (1998/1999) to 2001.
  • FIG. 2 depicts the distribution of pneumococcal isolates with resistance to penicillin (PCN) in children ⁇ 5 years of age (1998).
  • FIG. 3 depicts the reverse cumulative distribution curves (RCDC) of OPA post-third dose results from the D118-P16 Prevnar trial.
  • serotype 1 In the US, the rate of IPD caused by serotype 1 in children under the age of 5 years is ⁇ 2%, about the same as for each of types 3 and 7F [1,6].
  • Serotypes 1 and 5 account for higher rates of IPD in US populations at high risk for invasive pneumococcal disease. Specifically, serotype 1 causes 3.5% of IPD in Alaskan native children ⁇ 2 years of age, and 18% in children 2-4 years of age [11]. Both serotype 1 and serotype 5 significantly cause disease in other parts of the world and in indigenous populations in developed countries [12,13,14].
  • Serotype 1 may also be associated with more severe disease as compared with other pneumococcal serotypes [15]. This observation is based on the difference in rates of case identification between the US and Europe, and the associated difference in medical practice. Overall, the incidence of IPD is lower in Europe than in the US. However, the percent of IPD caused by serotype 1 in Europe is disproportionately higher than in the US (6-7%, vs. 1-2%, respectively). In Europe, blood cultures are obtained predominantly from hospitalized children. In the US, it is routine medical practice to obtain blood cultures in an outpatient setting from children presenting with fever ⁇ 39° C. and elevated white blood cell counts.
  • serotype 1 the lower percent of disease caused by serotype 1 in the US may be diluted by higher rates of other serotypes causing milder disease, while the higher percent in Europe reflects more serious disease.
  • seroepidemiology studies of children with complicated pneumonia demonstrate that serotype 1 is disproportionately represented [16,17,18]. This suggests that inclusion of serotype 1 may reduce the amount of severe pneumococcal disease, as well as, contribute to a total reduction in invasive pneumococcal disease.
  • serotypes 3 and 7F will increase coverage against IPD in most areas of the world by approximately 3%-7%, and in Asia by around 9%. Thus, an 11-valent vaccine would cover 50% in Asia and around 80% of IPD in all other regions [1,2]. These serotypes are also important with respect to otitis media coverage [19]. In a multinational study of pneumococcal serotypes causing otitis media, Hausdorff et al. found serotype 3 to be the 8th most common middle ear fluid isolate overall [20]. Serotype 3 accounted for up to 8.7% of pneumococcal serotypes associated with otitis media. Thus, the importance of types 3 and 7F in otitis media, as well as in IPD, warrants their inclusion in a pneumococcal conjugate vaccine.
  • opsonophagocytic assay results from infants who had received doses of 11-Pn-PD failed to show antibody responses for serotype 3 at levels comparable to other tested serotypes (Gatchalian et al., 17 th Annual Meeting of the Eur. Soc. Paed. Inf. Dis. (ESPID), Poster No. 4, P1A Poster Session 1, Istanbul Turkey, Mar. 27, 2001).
  • the vaccine did not provide protection against episodes caused by serotype 3 (Prymula et al. (2006) Lancet, 367:740-748).
  • a pneumococcal conjugate vaccine comprising capsular polysaccharides from serotype 3 and capable of eliciting an immunogenic response to serotype 3 polysaccharides provides a significant improvement over the existing state of the art.
  • the licensed unconjugated pneumococcal polysaccharide vaccines (for use in persons at least two years of age) have contained 6A or 6B capsular polysaccharide but not both [21]. Immunogenicity data generated at the time of formulation of the 23-valent pneumococcal polysaccharide vaccine demonstrated that a 6B monovalent vaccine induced antibody to both the 6A and 6B capsules.
  • the 19A and 19F capsules are quite different due to the presence of two additional side chains in the 19A polysaccharide.
  • immune responses measured in human volunteers immunized with 19F polysaccharide vaccine showed that responses to 19F were induced in 80% of subjects, but only 20% of subjects had a response to 19A [26].
  • Low levels of cross-reactive IgG and OPA responses to serotype 19A after immunization with 19F polysaccharide have also been documented in trials with conjugate vaccines as well [24,26].
  • Post-marketing IPD surveillance data is also available from a case-control trial conducted by the Centers for Disease Control to evaluate the effectiveness of Prevnar [33]. Cases of pneumococcal invasive disease occurring in children 3 to 23 months of age were identified in the surveillance laboratories and matched with three control cases by age and zip code. After obtaining consent, medical and immunization history (subjects were considered immunized if they had received at least one dose of Prevnar) was obtained from parents and medical providers for cases and controls. The preliminary results were presented at the 2003 ICAAC meeting and a summary of the findings for 6B, 19F, 19A and 6A disease is presented in Table 2.
  • the present invention provides a multivalent immunogenic composition
  • a multivalent immunogenic composition comprising 13 distinct polysaccharide-protein conjugates, wherein each of the conjugates contains a different capsular polysaccharide conjugated to a carrier protein, and wherein the capsular polysaccharides are prepared from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F of Streptococcus pneumoniae , together with a physiologically acceptable vehicle.
  • One such carrier protein is the diphtheria toxoid designated CRM 197 .
  • the immunogenic composition may further comprise an adjuvant, such as an aluminum-based adjuvant, such as aluminum phosphate, aluminum sulfate and aluminum hydroxide.
  • Capsular polysaccharides are prepared by standard techniques known to those skilled in the art.
  • capsular polysaccharides are prepared from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F of Streptococcus pneumoniae .
  • These pneumococcal conjugates are prepared by separate processes and formulated into a single dosage formulation. For example, in one embodiment, each pneumococcal polysaccharide serotype is grown in a soy-based medium. The individual polysaccharides are then purified through centrifugation, precipitation, ultra-filtration, and column chromatography. The purified polysaccharides are chemically activated to make the saccharides capable of reacting with the carrier protein.
  • each capsular polysaccharide is separately conjugated to a carrier protein to form a glycoconjugate.
  • each capsular polysaccharide is conjugated to the same carrier protein.
  • the conjugation is effected by reductive amination.
  • Carrier proteins are preferably proteins that are non-toxic and non-reactogenic and obtainable in sufficient amount and purity. Carrier proteins should be amenable to standard conjugation procedures.
  • CRM 197 is used as the carrier protein.
  • CRM 197 (Wyeth, Sanford, N.C.) is a non-toxic variant (i.e., toxoid) of diphtheria toxin isolated from cultures of Corynebacterium diphtheria strain C7 ( ⁇ 197) grown in casamino acids and yeast extract-based medium.
  • CRM 197 is purified through ultra-filtration, ammonium sulfate precipitation, and ion-exchange chromatography.
  • CRM 197 is prepared recombinantly in accordance with U.S. Pat. No. 5,614,382, which is hereby incorporated by reference.
  • Other diphtheria toxoids are also suitable for use as carrier proteins.
  • Suitable carrier proteins include inactivated bacterial toxins such as tetanus toxoid, pertussis toxoid, cholera toxoid (e.g., as described in International Patent Application WO2004/083251 [38]), E. coli LT, E. coli ST, and exotoxin A from Pseudomonas aeruginosa .
  • Bacterial outer membrane proteins such as outer membrane complex c (OMPC), porins, transferrin binding proteins, pneumolysin, pneumococcal surface protein A (PspA), pneumococcal adhesin protein (PsaA), C5a peptidase from Group A or Group B streptococcus , or Haemophilus influenzae protein D, can also be used.
  • Other proteins such as ovalbumin, keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA) or purified protein derivative of tuberculin (PPD) can also be used as carrier proteins.
  • the polysaccharide-protein conjugates are purified (enriched with respect to the amount of polysaccharide-protein conjugate) by a variety of techniques. These techniques include concentration/diafiltration operations, precipitation/elution, column chromatography, and depth filtration. See examples below.
  • the individual glycoconjugates are compounded to formulate the immunogenic composition of the present invention, which can be used as a vaccine.
  • Formulation of the immunogenic composition of the present invention can be accomplished using art-recognized methods.
  • the 13 individual pneumococcal conjugates can be formulated with a physiologically acceptable vehicle to prepare the composition.
  • physiologically acceptable vehicles include, but are not limited to, water, buffered saline, polyols (e.g., glycerol, propylene glycol, liquid polyethylene glycol) and dextrose solutions.
  • the immunogenic composition will comprise one or more adjuvants.
  • an “adjuvant” is a substance that serves to enhance the immunogenicity of an immunogenic composition of this invention.
  • adjuvants are often given to boost the immune response and are well known to the skilled artisan.
  • Suitable adjuvants to enhance effectiveness of the composition include, but are not limited to:
  • aluminum salts such as aluminum hydroxide, aluminum phosphate, aluminum sulfate, etc.
  • oil-in-water emulsion formulations with or without other specific immunostimulating agents such as muramyl peptides (defined below) or bacterial cell wall components), such as, for example,
  • saponin adjuvants such as Quil A or STIMULONTM QS-21 (Antigenics, Framingham, Mass.) (U.S. Pat. No. 5,057,540) may be used or particles generated therefrom such as ISCOMs (immunostimulating complexes);
  • AGP is 2-[(R)-3-Tetradecanoyloxytetradecanoylamino]ethyl 2-Deoxy-4-O-phosphono-3-O—[(R)-3-tetradecanoyloxytetradecanoyl]-2-[(R)-3-tetradecanoyloxytetradecanoylamino]-b-D-glucopyranoside, which is also know as 529 (formerly known as RC529), which is formulated as an aqueous form or as a stable emulsion, synthetic polynucleotides such as oligonucleotides containing CpG motif(s) (U.S. Pat. No. 6,207,646);
  • cytokines such as interleukins (e.g., IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, IL-15, IL-18, etc.), interferons (e.g., gamma interferon), granulocyte macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), costimulatory molecules B7-1 and B7-2, etc.;
  • interleukins e.g., IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, IL-15, IL-18, etc.
  • interferons e.g., gamma interferon
  • GM-CSF granulocyte macrophage colony stimulating factor
  • M-CSF macrophage colony stimulating factor
  • TNF tumor necrosis factor
  • a bacterial ADP-ribosylating toxin such as a cholera toxin (CT) either in a wild-type or mutant form, for example, where the glutamic acid at amino acid position 29 is replaced by another amino acid, preferably a histidine, in accordance with published international patent application number WO 00/18434 (see also WO 02/098368 and WO 02/098369), a pertussis toxin (PT), or an E. coli heat-labile toxin (LT), particularly LT-K63, LT-R72, CT-S109, PT-K9/G129 (see, e.g., WO 93/13302 and WO 92/19265); and
  • CT cholera toxin
  • Muramyl peptides include, but are not limited to, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanine-2-(1′-2′ dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (MTP-PE), etc.
  • the vaccine formulations of the present invention can be used to protect or treat a human susceptible to pneumococcal infection, by means of administering the vaccine via a systemic or mucosal route.
  • administrations can include injection via the intramuscular, intraperitoneal, intradermal or subcutaneous routes; or via mucosal administration to the oral/alimentary, respiratory or genitourinary tracts.
  • intranasal administration is used for the treatment of pneumonia or otitis media (as nasopharyngeal carriage of pneumococci can be more effectively prevented, thus attenuating infection at its earliest stage).
  • each vaccine dose is selected as an amount that induces an immunoprotective response without significant, adverse effects. Such amount can vary depending upon the pneumococcal serotype. Generally, each dose will comprise 0.1 to 100 ⁇ g of polysaccharide, particularly 0.1 to 10 ⁇ g, and more particularly 1 to 5 ⁇ g.
  • Optimal amounts of components for a particular vaccine can be ascertained by standard studies involving observation of appropriate immune responses in subjects. Following an initial vaccination, subjects can receive one or several booster immunizations adequately spaced.
  • the 13vPnC vaccine is a sterile liquid formulation of pneumococcal capsular polysaccharides of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F individually conjugated to CRM 197 .
  • Each 0.5 mL dose is formulated to contain: 2 ⁇ g of each saccharide, except for 6B at 4 ⁇ g; approximately 29 ⁇ g CRM 197 carrier protein; 0.125 mg of elemental aluminum (0.5 mg aluminum phosphate) adjuvant; and sodium chloride and sodium succinate buffer as excipients.
  • the liquid is filled into single dose syringes without a preservative. After shaking, the vaccine is a homogeneous, white suspension ready for intramuscular administration.
  • the choice of dose level for the 13vPnC vaccine is similar to the marketed 7vPnC vaccine (Prevnar).
  • the 2 ⁇ g saccharide dose level was selected for all serotypes, except for 6B, which is at 4 ⁇ g per dose.
  • the 7vPnC vaccine has shown desirable safety, immunogenicity, and efficacy against IPD in the 2 ⁇ g saccharide dose level for serotypes 4, 9V, 14, 18C, 19F and 23F, and at the 4 ⁇ g dose for 6B.
  • the immunization schedule can follow that designated for the 7vPnC vaccine.
  • the routine schedule for infants and toddlers against invasive disease caused by S. pneumoniae due to the serotypes included in the 13vPnC vaccine is 2, 4, 6 and 12-15 months of age.
  • the compositions of this invention are also suitable for use with older children, adolescents and adults.
  • compositions of this invention may further include one or more additional antigens for use against otitis media caused by infection with other bacteria.
  • additional antigens for use against otitis media caused by infection with other bacteria.
  • bacteria include nontypable Haemophilus influenza, Moraxella catarrhalis (formerly known as Branhamella catarrhalis ) and Alloiococcus otitidis.
  • nontypable Haemophilus influenzae antigens suitable for inclusion include the P4 protein, also known as protein “e” (U.S. Pat. No. 5,601,831; International Patent Application WO03/078453), the P6 protein, also known as the PAL or the PBOMP-1 protein (U.S. Pat. No. 5,110,908; International Patent Application WO0100790), the P5 protein (U.S. Reissue Patent No. 37,741), the Haemophilus adhesion and penetration protein (U.S. Pat. Nos. 6,245,337 and 6,676,948), the LKP tip adhesin protein (U.S. Pat. No. 5,643,725) and the NucA protein (U.S. Pat. No. 6,221,365).
  • P4 protein also known as protein “e” (U.S. Pat. No. 5,601,831; International Patent Application WO03/078453)
  • the P6 protein also known as the PAL or the PBOMP-1 protein (U
  • Moraxella catarrhalis antigens suitable for inclusion include the UspA2 protein (U.S. Pat. Nos. 5,552,146, 6,310,190), the CD protein (U.S. Pat. No. 5,725,862), the E protein (U.S. Pat. No. 5,948,412) and the 74 kilodalton outer membrane protein (U.S. Pat. No. 6,899,885).
  • Alloiococcus otitidis antigens suitable for inclusion include those identified in International Patent Application WO03/048304.
  • compositions of this invention may also include one or more proteins from Streptococcus pneumoniae .
  • Streptococcus pneumoniae proteins suitable for inclusion include those identified in International Patent Application WO02/083855, as well as that described in International Patent Application WO02/053761.
  • compositions of this invention may further include one or more proteins from Neisseria meningitidis type B.
  • Neisseria meningitidis type B proteins suitable for inclusion include those identified in International Patent Applications WO03/063766, WO2004/094596, WO01/85772, WO02/16612 and WO01/87939.
  • Partial oxidation of carbohydrates in polysaccharides has been effectively utilized to generate aldehyde groups which are then coupled to the lysine residues of carrier proteins to generate immunogenic conjugates (i.e., compositions, such as vaccines, useful for stimulating or eliciting a specific immune response in a vertebrate).
  • immunogenic conjugates i.e., compositions, such as vaccines, useful for stimulating or eliciting a specific immune response in a vertebrate.
  • a general prerequisite for the generation of the aldehyde groups is the presence of vicinal (adjacent) hydroxyl groups. In some polysaccharides, some of the hydroxyl groups are unavailable since they are blocked by other functionalities.
  • the O-acetyl groups are a hindrance for efficient oxidation, and selective removal of some of these groups (i.e., the introduction of mild de-O-acetylation of the polysaccharide prior to oxidation) facilitates the oxidation and improves the conjugation efficiency.
  • the Pn 1 polysaccharide is first partially de-O-acetylated by mild hydrolysis in an alkaline pH buffer.
  • alkaline pH buffers include, but are not limited to, a bicarbonate/carbonate buffer (such as sodium bicarbonate/carbonate), glycine, imidazole, and TRIS-EDTA.
  • De-O-acetylation is followed by neutralization using a mild acid, such as acetic acid, citric acid or carbonic acid, or a low ionic strength mineral acid (e.g., hydrochloric acid).
  • Partial oxidation to produce “activated” Pn 1 polysaccharide is carried out following neutralization using controlled amounts of an oxidizing agent. Any selective oxidizing agent which oxidizes a terminal hydroxyl group to an aldehyde, including specific sugar oxidases, can be used (e.g., sodium or potassium periodate).
  • the activated Pn 1 polysaccharide is then optionally purified (e.g., by diafiltration versus buffered saline).
  • Activated Pn 1 polysaccharide can be compounded with a carrier protein.
  • Carrier proteins are chosen to increase the immunogenicity of the bound Pn 1 polysaccharide and/or to elicit antibodies against the carrier protein which are diagnostically, analytically and/or therapeutically beneficial.
  • Covalent linking of an antigenic molecule (e.g., a polysaccharide) to a carrier confers enhanced immunogenicity and T-cell dependence (Pozsgay et al. (1999) PNAS, 96:5194-97; Lee et al. (1976) J. Immunol., 116:1711-18; Dintzis et al. (1976) PNAS, 73:3671-75).
  • useful carrier proteins include inactivated bacterial toxins such as tetanus toxoid, pertussis toxoid, cholera toxoid (e.g., as described in International Patent Application WO2004/083251), E. coli LT, E. coli ST, and exotoxin A from Pseudomonas aeruginosa .
  • Bacterial outer membrane proteins such as outer membrane complex c, porins, transferrin binding proteins, pneumolysin, pneumococcal surface protein A, pneumococcal adhesin protein, C5a peptidase from Group A or Group B streptococcus , or Haemophilus influenzae protein D, can also be used.
  • Other proteins such as ovalbumin, keyhole limpet hemocyanin, bovine serum albumin, or purified protein derivative of tuberculin can also be used as carrier proteins.
  • a preferred carrier protein is the mutated diphtheria toxin CRM 197 . Following compounding with the carrier protein, the activated Pn 1 polysaccharide/carrier protein mixture is optionally frozen (e.g., shell frozen) and co-lyophilized.
  • Conjugation is carried out by reacting the activated Pn 1 polysaccharide/carrier protein mixture with a reducing agent, such as sodium cyanoborohydride. Unreacted aldehydes are then capped by a sodium borohydride reduction.
  • the conjugate is purified (e.g., by diafiltration versus phosphate buffer followed by buffered saline), giving a final batch concentrate of the glycoconjugate in buffered saline.
  • S. pneumoniae serotype 1 was obtained from the American Type Culture Collection, ATCC, strain 6301. Several generations of seed stocks were created in order to expand the strain and remove components of animal origin (generations F1, F2, and F3). Two additional generations of seed stocks were produced. The first additional generation was made from an F3 vial, and the subsequent generation was made from a vial of the first additional generation. Seed vials were stored frozen ( ⁇ 70° C.) with synthetic glycerol as a cryopreservative. In addition to frozen vials, lyophilized vials were prepared for the F4 generation. For cell bank preparation, all cultures were grown in a soy-based medium. Prior to freezing, cells were concentrated by centrifugation, spent medium was removed, and cell pellets were re-suspended in fresh medium containing a cryopreservative, such as synthetic glycerol.
  • a cryopreservative such as synthetic glycerol.
  • Cultures from the working cell bank were used to inoculate seed bottles containing a soy-based medium. The bottles were incubated at 36° C. ⁇ 2° C. without agitation until growth requirements were met.
  • a seed bottle was used to inoculate a seed fermentor containing soy-based medium.
  • a pH of about 7.0 was maintained with sterile sodium carbonate solution.
  • the seed fermentor was used to inoculate the production fermentor containing soy-based medium.
  • the pH was maintained with sterile sodium carbonate solution.
  • the fermentation was terminated after cessation of growth or when the working volume of the fermentor was reached.
  • the fermentation pH of about 7.0 was maintained with 3N NaOH.
  • the seed fermentor was used to inoculate the production fermentor containing soy-based medium.
  • the pH was maintained with 3N NaOH.
  • the fermentation was terminated after cessation of growth or when the working volume of the fermentor was reached.
  • An appropriate amount of sterile 12% deoxycholate sodium was added to the culture to obtain a 0.12% concentration in the broth, to lyse the bacterial cells and release cell-associated polysaccharide.
  • the fermentor contents were held, with agitation, for a time interval between 8 and 24 hours at a temperature between 7° C.
  • the pH of the lysed culture broth was adjusted to approximately pH 5.0 with 50% acetic acid. After a hold time without agitation, for a time interval between 12 and 24 hours at a temperature between 15° C. and 25° C., a significant portion of the previously soluble proteins dropped out of solution as a solid precipitate with little loss or degradation of the polysaccharide, which remained in solution. The solution with the precipitate was then clarified by continuous flow centrifugation followed by depth filtration and 0.45 ⁇ m microfiltration.
  • the purification of the pneumococcal polysaccharide consisted of several concentration/diafiltration operations, precipitation/elution, column chromatography, and depth filtration steps. All procedures were performed at room temperature unless otherwise specified.
  • Clarified broth from the fermentor cultures of S. pneumoniae serotype 1 were concentrated and diafiltered using a 100 kDa MWCO (kilodalton molecular weight cutoff) filter. Diafiltration was accomplished using sodium phosphate buffer at neutral pH. Diafiltration removed the low molecular weight medium components from the higher molecular weight biopolymers such as nucleic acid, protein and polysaccharide.
  • the polysaccharide was precipitated from the concentrated and diafiltered solution by adding hexadecyltrimethyl ammonium bromide (HB) from a stock solution to give a final concentration of 1% HB (w/v).
  • HB hexadecyltrimethyl ammonium bromide
  • the polysaccharide/HB precipitate was captured on a depth filter and the filtrate was discarded.
  • the polysaccharide precipitate was resolubilized and eluted by recirculating a sodium chloride solution through the precipitate-containing depth filter. The filters were then rinsed with additional sodium chloride solution.
  • Sodium iodide (NaI) was added to the polysaccharide solution from a stock NaI solution to achieve a final concentration of 0.5% to precipitate HB.
  • the precipitate was removed by depth filtration.
  • the filtrate contains the target polysaccharide.
  • the precipitation vessel and the filter were rinsed with a NaCl/NaI solution and the rinse was combined with the partially purified polysaccharide solution. The filter was discarded.
  • the polysaccharide was then filtered through a 0.2 ⁇ m filter.
  • the polysaccharide solution was concentrated on a 30 kDa MWCO ultrafilter and diafiltered with a sodium chloride solution.
  • the partially purified polysaccharide solution was further purified by filtration through a depth filter impregnated with activated carbon. After filtration, the carbon filter was rinsed with a sodium chloride solution. The rinse is combined with the polysaccharide solution, which is then filtered through a 0.2 ⁇ m filter.
  • the polysaccharide solution was concentrated on a 30 kDa MWCO ultrafilter and adjusted with a 1M sodium phosphate buffer to achieve a final concentration of 0.025 M sodium phosphate.
  • the pH was checked and adjusted to 7.0 ⁇ 0.2.
  • the ceramic hydroxyapatite (HA) column was equilibrated with sodium phosphate buffer containing sodium chloride to obtain the appropriate conductivity ( ⁇ 15 ⁇ S).
  • the polysaccharide solution was then loaded onto the column. Under these conditions, impurities bound to the resin and the polysaccharide was recovered in the flow-through from the column.
  • the polysaccharide solution was filtered through 0.2 ⁇ m inline filters located before and after the column.
  • the polysaccharide solution was concentrated using a 30 kDa MWCO filter. The concentrate was then diafiltered with Water for Injection (WFI).
  • WFI Water for Injection
  • the diafiltered polysaccharide solution was filtered through a 0.2 ⁇ m membrane filter into polypropylene bottles. Samples were removed for release testing and the purified polysaccharide was stored frozen at ⁇ 25° ⁇ 5° C.
  • the 1H-NMR data was consistent with the chemical structure by the assignment of signals assigned to the protons of the polysaccharide molecule.
  • the 1H-NMR spectrum showed a series of well-resolved signals (protons from the methyl group) for the quantitation of the O-acetyl functional group in the polysaccharide.
  • the identity of the monovalent polysaccharide was confirmed by countercurrent immunoelectrophoresis using specific antisera.
  • MALLS multiangle laser light scattering
  • Size exclusion chromatography media (CL-4B) was used to profile the relative molecular size distribution of the polysaccharide.
  • Containers of purified polysaccharide were thawed and combined in a reaction vessel.
  • 0.2 M sodium carbonate, pH 9.0 was added for partial deacetylation (hydrolysis) for 3 hours at 50° C.
  • the reaction was cooled to 20° C. and neutralization was performed by 0.2 M acetic acid. Oxidation in the presence of sodium periodate was performed by incubation at 2-8° C., and the mixture was stirred for 15-21 hours.
  • the activation reaction mixture was concentrated and diafiltered 10 ⁇ with 0.9% NaCl using a 30K MWCO membrane.
  • the retentate was 0.2 ⁇ m filtered.
  • the activated saccharide was filled into 100 mL glass lyophilization bottles and shell-frozen at ⁇ 75° C. and lyophilized.
  • Shell-freezing is a method for preparing samples for lyophilization (freeze-drying). Flasks are automatically rotated by motor driven rollers in a refrigerated bath containing alcohol or any other appropriate fluid. A thin coating of product is evenly frozen around the inside “shell” of a flask, permitting a greater volume of material to be safely processed during each freeze-drying run.
  • These automatic, refrigerated units provide a simple and efficient means of pre-freezing many flasks at a time, producing the desired coatings inside, and providing sufficient surface area for efficient freeze-drying.
  • Bottles of lyophilized material were brought to room temperature and resuspended in CRM 197 solution at a saccharide/protein ratio of 2:1.
  • 1M sodium phosphate buffer was added to a final 0.2M ionic strength and a pH of 7.5, then sodium cyanoborohydride was added.
  • the reaction was incubated at 23° C. for 18 hours, followed by a second incubation at 37° C. for 72 hours. Following the cyanoborohydride incubations, the reaction mixture was diluted with cold saline followed by the addition of 1M sodium carbonate to adjust the reaction mixture to pH 9.0. Unreacted aldehydes were quenched by addition of sodium borohydride by incubation at 23° C. for 3-6 hours.
  • the reaction mixture was diluted 2-fold with saline and transferred through a 0.45-5 ⁇ m prefilter into a retentate vessel.
  • the reaction mixture is diafiltered 30 ⁇ with 0.15 M phosphate buffer, pH 6, and 20 ⁇ with saline.
  • the retentate was filtered through a 0.2 ⁇ m filter.
  • the conjugate solution was diluted to a target of 0.5 mg/mL in 0.9% saline, and then sterile filtered into final bulk concentrate (FBC) containers in a Class 100 hood.
  • the conjugate was stored at 2-8° C.
  • Size exclusion chromatography media (CL-4B) was used to profile the relative molecular size distribution of the conjugate.
  • the saccharide and protein concentrations were determined by the uronic acid and Lowry assays, respectively.
  • O-acetyl content was measured by the Hestrin method (Hestrin et. al., J. Biol. Chem. 1949, 180, p. 249).
  • the ratio of O-acetyl concentration to total saccharide concentration gave ⁇ moles of O-acetyl per mg of saccharide.
  • S. pneumoniae serotype 3 was obtained from Dr. Robert Austrian, University of Pennsylvania, Philadelphia, Pa. For preparation of the cell bank system, see Example 1.
  • Cultures from the working cell bank were used to inoculate seed bottles containing soy-based medium. The bottles were incubated at 36° C. ⁇ 2° C. without agitation until growth requirements were met.
  • a seed bottle was used to inoculate a seed fermentor containing soy-based medium.
  • a pH of about 7.0 was maintained with sterile sodium carbonate solution.
  • the seed fermentor was used to inoculate an intermediate seed fermentor.
  • the intermediate seed fermentor was used to inoculate the production fermentor.
  • the pH was maintained with sterile sodium carbonate solution. The fermentation was terminated after the working volume of the fermentor was reached.
  • the purification of the pneumococcal polysaccharide consisted of several concentration/diafiltration operations, precipitation/elution, column chromatography, and depth filtration steps. All procedures were performed at room temperature unless otherwise specified.
  • Clarified broth from the fermentor cultures of S. pneumoniae serotype 3 were concentrated and diafiltered using a 100 kDa MWCO filter. Diafiltration was accomplished using sodium phosphate buffer at neutral pH. Diafiltration removed the low molecular weight medium components from the higher molecular weight biopolymers such as nucleic acid, protein and polysaccharide.
  • hexadecyltrimethyl ammonium bromide Prior to the addition of hexadecyltrimethyl ammonium bromide (HB), a calculated volume of a NaCl stock solution was added to the concentrated and diafiltered polysaccharide solution to give a final concentration of 0.25 M NaCl. The polysaccharide was then precipitated by adding HB from a stock solution to give a final concentration of 1% HB (w/v). The polysaccharide/HB precipitate was captured on a depth filter and the filtrate was discarded. The polysaccharide precipitate was resolubilized and eluted by recirculating a sodium chloride solution through the precipitate-containing depth filter. The filters were then rinsed with additional sodium chloride solution.
  • HB hexadecyltrimethyl ammonium bromide
  • Sodium iodide (NaI) was added to the polysaccharide solution from a stock NaI solution to achieve a final concentration of 0.5% to precipitate HB.
  • the precipitate was removed by depth filtration.
  • the filtrate contained the target polysaccharide.
  • the precipitation vessel and the filter were rinsed with a NaCl/NaI solution and the rinse was combined with the partially purified polysaccharide solution. The filter was discarded.
  • the polysaccharide was then filtered through a 0.2 ⁇ m filter.
  • the polysaccharide solution was concentrated on a 30 kDa MWCO ultrafilter and diafiltered with a sodium chloride solution.
  • the partially purified polysaccharide solution was further purified by filtration through a depth filter impregnated with activated carbon. After filtration, the carbon filter was rinsed with a sodium chloride solution. The rinse was combined with the polysaccharide solution, which was then filtered through a 0.2 ⁇ m filter.
  • the polysaccharide solution was concentrated on a 30 kDa MWCO ultrafilter and adjusted with a 1M sodium phosphate buffer to achieve a final concentration of 0.025M sodium phosphate.
  • the pH was checked and adjusted to 7.0 ⁇ 0.2.
  • the ceramic hydroxyapatite (HA) column was equilibrated with sodium phosphate buffer containing sodium chloride to obtain the appropriate conductivity (15 ⁇ S).
  • the polysaccharide solution was then loaded onto the column. Under these conditions, impurities bound to the resin and the polysaccharide was recovered in the flow-through from the column.
  • the polysaccharide was flushed through the column with buffer and was filtered through a 0.2 ⁇ m filter.
  • the polysaccharide solution was concentrated using a 30 kDa MWCO filter. The concentrate was then diafiltered with WFI.
  • the diafiltered polysaccharide solution was filtered through a 0.2 ⁇ m membrane filter into stainless steel containers. Samples were removed for release testing and the purified polysaccharide was stored frozen at ⁇ 25° ⁇ 5° C.
  • the 1H-NMR data was consistent with the chemical structure by the assignment of signals assigned to the protons of the polysaccharide molecule.
  • the identity of the monovalent polysaccharide was confirmed by countercurrent immunoelectrophoresis using specific antisera.
  • High performance gel filtration chromatography coupled with refractive index and multiangle laser light scattering (MALLS) detectors, was used in conjunction with the sample concentration to calculate the molecular weight.
  • MALLS multiangle laser light scattering
  • Size exclusion chromatography media (CL-4B) was used to profile the relative molecular size distribution of the polysaccharide.
  • Containers of purified serotype 3 saccharide were thawed and combined in a reaction vessel.
  • WFI and 2M acetic acid were added to a final concentration of 0.2M and 2 mg/mL saccharide.
  • the temperature of the solution was raised to 85° C. for one hour to hydrolyze the polysaccharide.
  • the reaction was cooled to ⁇ 25° C. and 1M magnesium chloride was added to a final concentration of 0.1M. Oxidation in the presence of sodium periodate was performed by incubation for 16-24 hours at 23° C.
  • the activation reaction mixture was concentrated and diafiltered 10 ⁇ with WFI using a 100K MWCO membrane.
  • the retentate was filtered through a 0.2- ⁇ m filter.
  • 0.2M sodium phosphate, pH 7.0 was added to the activated saccharide to a final concentration of 10 mM and a pH of 6.0-6.5.
  • CRM 197 carrier protein was mixed with the saccharide solution to a ratio of 2 g of saccharide per 1 g of CRM 197 .
  • the combined saccharide/protein solution was filled into 100 mL glass lyophilization bottles with a 50 mL target fill, shell-frozen at ⁇ 75° C., and lyophilized.
  • Bottles of co-lyophilized saccharide/protein material were brought to room temperature and resuspended in 0.1M sodium phosphate buffer, pH 7.0, to a final saccharide concentration of 20 mg/mL.
  • the pH was adjusted to 6.5 and then a 0.5 molar equivalent of sodium cyanoborohydride was added.
  • the reaction was incubated at 37° C. for 48 hours. Following the cyanoborohydride incubation, the reaction mixture was diluted with cold 5 mM succinate/0.9% saline buffer. Unreacted aldehydes were quenched by the addition of sodium borohydride and incubation at 23° C. for 3-6 hours.
  • the reaction mixture was transferred through a 0.45-5 ⁇ m prefilter into a retentate vessel.
  • the reaction mixture was diafiltered 30 ⁇ with 0.1M phosphate buffer (pH 9), 20 ⁇ with 0.15M phosphate butter (pH 6), and 20 ⁇ with 5 mM succinate/0.9% saline.
  • the retentate was filtered through a 0.2- ⁇ m filter.
  • the conjugate solution was diluted to a saccharide target of 0.5 mg/mL, and then sterile filtered into FBC containers in a Class 100 hood.
  • the conjugate was stored at 2-8° C.
  • Size exclusion chromatography media (CL-4B) was used to profile the relative molecular size distribution of the conjugate.
  • the saccharide and protein concentrations were determined by the Anthrone and Lowry assays, respectively.
  • S. pneumoniae serotype 5 was obtained from Dr. Gerald Schiffman of the State University of New York, Brooklyn, N.Y. For preparation of the cell bank system, see Example 1. For fermentation, harvesting, purification and characterization of the polysaccharide, see Example 1.
  • Cultures from the working cell bank were used to inoculate seed bottles containing a soy-based medium and a 10 mM sterile NaHCO 3 solution. The bottles were incubated at 36° C. ⁇ 2° C. without agitation until growth requirements were met.
  • a seed bottle was used to inoculate a seed fermentor containing soy-based medium and a 10 mM sterile NaHCO 3 solution.
  • a pH of about 7.0 was maintained with 3N NaOH.
  • the seed fermentor was used to inoculate the production fermentor containing soy-based medium with a 10 mM NaHCO 3 concentration. The pH was maintained with 3N NaOH.
  • the fermentation was terminated after cessation of growth or when the working volume of the fermentor was reached.
  • An appropriate amount of sterile 12% sodium deoxycholate was added to the culture to obtain a 0.12% concentration in the broth, to lyse the bacterial cells and release cell-associated polysaccharide.
  • the fermentor contents were held, with agitation, for a time interval between 8 and 24 hours at a temperature between 7° C. and 13° C. to assure that complete cellular lysis and polysaccharide release had occurred. Agitation during this hold period prevented lysate sediment from settling on the fermentor walls and pH probe, thereby allowing the pH probe integrity to be maintained.
  • the pH of the lysed culture broth was adjusted to approximately pH 4.5 with 50% acetic acid. After a hold time without agitation, for a time interval between 12 and 24 hours at a temperature between 15° C. and 25° C., a significant portion of the previously soluble proteins dropped out of solution as a solid precipitate with little loss or degradation of the polysaccharide, which remained in solution.
  • the solution with the precipitate was then clarified by continuous flow centrifugation followed by depth filtration and 0.45 ⁇ m microfiltration.
  • Containers of serotype 5 saccharide were thawed and combined in a reaction vessel.
  • 0.1M sodium acetate, pH 4.7 was added followed by oxidation in the presence of sodium periodate by incubation for 16-22 hours at 23° C.
  • the activation reaction mixture was concentrated and diafiltered 10 ⁇ with WFI using a 100K MWCO membrane.
  • the retentate was filtered through a 0.2 ⁇ m filter.
  • the serotype 5 activated saccharide was combined with CRM 197 at a ratio of 0.8:1.
  • the combined saccharide/protein solution was filled into 100 mL glass lyophilization bottles (50 mL target fill), shell-frozen at ⁇ 75° C., and co-lyophilized.
  • Bottles of co-lyophilized material were brought to room temperature and resuspended in 0.1M sodium phosphate, pH 7.5, and sodium cyanoborohydride was added. The reaction was incubated at 30° C. for 72 hours, followed by a second addition of cyanoborohydride and incubated at 30° C. for 20-28 hours.
  • reaction mixture was diluted 2-fold with saline and transferred through a 0.45-5 ⁇ m prefilter into a retentate vessel.
  • the reaction mixture was diafiltered 30 ⁇ with 0.01M phosphate buffer, pH 8, 20 ⁇ with 0.15M phosphate buffer, pH 6, and 20 ⁇ with saline.
  • the retentate was filtered through a 0.2 ⁇ m filter.
  • the conjugate solution was diluted to a saccharide target of 0.5 mg/mL, and then sterile filtered into FBC containers in a Class 100 hood.
  • the conjugate was stored at 2-8° C.
  • S. pneumoniae serotype 6A was obtained from Dr. Gerald Schiffman of the State University of New York, Brooklyn, N.Y.
  • Serotype 6A polysaccharide is a high molecular weight polymer that had to be reduced in size prior to oxidation.
  • Containers of serotype 6A saccharide were thawed and combined in a reaction vessel.
  • 2 M acetic acid was added to a final concentration of 0.1M for hydrolysis for 1.5 hours at 60° C.
  • the reaction was cooled to 23° C. and neutralization was performed by adjusting the reaction mixture with 1 M NaOH to pH 6. Oxidation in the presence of sodium periodate was performed by incubation at 23° C. for 14-22 hours.
  • the activation reaction mixture was concentrated and diafiltered 10 ⁇ with WFI using a 100K MWCO membrane.
  • the retentate was filtered through a 0.2 ⁇ m filter.
  • Serotype 6A was compounded with sucrose and filled into 100 mL glass lyophilization bottles (50 mL target fill) and shell-frozen at ⁇ 75° C. and lyophilized.
  • Bottles of lyophilized material were brought to room temperature and resuspended in dimethylsulfoxide (DMSO) at a saccharide/protein ratio of 1:1. After addition of sodium cyanoborohydride, the reaction mixture was incubated at 23° C. for 18 hours. Following the cyanoborohydride incubation, the reaction mixture was diluted with cold saline. Unreacted aldehydes were quenched by addition of sodium borohydride by incubation at 23° C. for 3-20 hours.
  • DMSO dimethylsulfoxide
  • the diluted reaction mixture was transferred through a 5 ⁇ m prefilter into a retentate vessel.
  • the reaction mixture was diafiltered 10 ⁇ with 0.9% NaCl and 30 ⁇ with succinate-buffered NaCl.
  • the retentate was filtered through a 0.2 ⁇ m filter.
  • the conjugate solution was diluted to a saccharide target of 0.5 mg/mL, and then sterile filtered into FBC containers in a Class 100 hood.
  • the conjugate was stored at 2-8° C.
  • S. pneumoniae serotype 7F was obtained from Dr. Gerald Schiffman of the State University of New York, Brooklyn, N.Y.
  • the purification of the pneumococcal polysaccharide consisted of several concentration/diafiltration operations, precipitation/elution, column chromatography, and depth filtration steps. All procedures were performed at room temperature unless otherwise specified.
  • Clarified broth from fermentor cultures of S. pneumoniae serotype 7F were concentrated and diafiltered using a 100 kDa MWCO filter. Diafiltration was accomplished using sodium phosphate buffer at neutral pH. Diafiltration removed the low molecular weight medium components from the higher molecular weight biopolymers such as nucleic acid, protein and polysaccharide.
  • Serotype 7F does not form a precipitate with HB. Instead, impurities were precipitated from the concentrated and diafiltered solution by adding the HB from a stock solution to a final concentration of 1% HB. The precipitate was captured on a depth filter and the filter was discarded. The polysaccharide was contained in the filtrate.
  • Sodium iodide (NaI) was added to the polysaccharide solution from a stock NaI solution to achieve a final concentration of 0.5% to precipitate HB.
  • the precipitate was removed by depth filtration.
  • the filtrate contained the target polysaccharide.
  • the precipitation vessel and the filter were rinsed with a NaCl/NaI solution and the rinses were combined with the partially purified polysaccharide solution. The filter was discarded.
  • the polysaccharide was then filtered through a 0.2 ⁇ m filter.
  • the polysaccharide solution was concentrated on a 30 kDa MWCO ultrafilter and diafiltered with a sodium chloride solution.
  • the partially purified polysaccharide solution was further purified by filtration through a depth filter impregnated with activated carbon. After filtration, the carbon filter was rinsed with a sodium chloride solution. The rinse was combined with the polysaccharide solution, which was then filtered through a 0.2 ⁇ m filter.
  • the polysaccharide solution was concentrated on a 30 kDa MWCO ultrafilter and adjusted with a 1M sodium phosphate buffer to achieve a final concentration of 0.025M sodium phosphate.
  • the pH was checked and adjusted to 7.0 ⁇ 0.2.
  • the ceramic hydroxyapatite (HA) column was equilibrated with sodium phosphate buffer containing sodium chloride to obtain the appropriate conductivity (15 ⁇ S).
  • the polysaccharide solution was then loaded onto the column. Under these conditions, impurities bound to the resin and the polysaccharide was recovered in the flow-through from the column.
  • the polysaccharide was flushed through the column with buffer and was filtered through a 0.2 ⁇ m filter.
  • the polysaccharide solution was concentrated using a 30 kDa MWCO filter. The concentrate was then diafiltered with WFI.
  • the diafiltered polysaccharide solution was filtered through a 0.2 ⁇ m membrane filter into stainless steel containers. Samples were removed for release testing and the purified polysaccharide was stored at 2°-8° C.
  • Oxidation in the presence of sodium periodate was performed by incubation for 16-24 hrs at 23° C.
  • the activation reaction mixture was concentrated and diafiltered 10 ⁇ with 10 mM NaOAc, pH 4.5, using a 100K MWCO membrane.
  • the retentate was filtered through a 0.2 ⁇ m filter.
  • Serotype 7F was filled into 100 mL glass lyophilization bottles (50 mL target fill) and shell-frozen at ⁇ 75° C. and lyophilized.
  • Bottles of lyophilized serotype 7F and CRM 197 were brought to room temperature and resuspended in DMSO at a saccharide/protein ratio of 1.5:1. After the addition of sodium cyanoborohydride, the reaction was incubated at 23° C. for 8-10 hours. Unreacted aldehydes were quenched by the addition of sodium borohydride by incubation at 23° C. for 16 hours.
  • the reaction mixture was diluted 10-fold with cold saline and transferred through a 5 ⁇ m prefilter into a retentate vessel.
  • the reaction mixture was diafiltered 10 ⁇ with 0.9% saline and 30 ⁇ with succinate-buffered saline.
  • the retentate was filtered through a 0.2 ⁇ m filter.
  • the conjugate solution was diluted to a saccharide target of 0.5 mg/mL 0.9% saline, and then sterile filtered into FBC containers in a Class 100 hood.
  • the conjugate was stored at 2-8° C.
  • S. pneumoniae serotype 19A was obtained from Dr. Gerald Schiffman of the State University of New York, Brooklyn, N.Y.
  • Example 1 For fermentation, harvesting and purification of the polysaccharide, see Example 7.
  • Containers of serotype 19A saccharide were thawed and combined in a reaction vessel.
  • Sodium acetate was added to 10 mM (pH 5.0) and oxidation was carried out in the presence of sodium periodate by incubation for 16-24 hrs at 23° C.
  • the activation reaction mixture was concentrated and diafiltered 10 ⁇ with 10 mM acetate, pH 5.0, using a 100K MWCO membrane.
  • the retentate was filtered through a 0.2 ⁇ m filter.
  • the activated saccharide was compounded with sucrose followed by the addition of CRM 197 .
  • the serotype 19A activated saccharide and CRM 197 mixture (0.8:1 ratio) was filled into 100 mL glass lyophilization bottles (50 mL target fill) and shell-frozen at ⁇ 75° C. and lyophilized.
  • Bottles of lyophilized material were brought to room temperature and resuspended in DMSO.
  • sodium cyanoborohydride 100 mg/ml was added. The reaction was incubated at 23° C. for 15 hours. Following the cyanoborohydride incubation, unreacted aldehydes were quenched by the addition of sodium borohydride by incubation at 23° C. for 3-20 hours.
  • the reaction mixture was diluted 10-fold with cold saline and transferred through a 5 ⁇ m prefilter into a retentate vessel.
  • the reaction mixture was diafiltered 10 ⁇ with 0.9% NaCl, 0.45- ⁇ m filtered, and 30 ⁇ with diafiltration using 5 mM succinate/0.9% NaCl buffer, pH 6.
  • the retentate was filtered through a 0.2 ⁇ m filter.
  • the conjugate solution was diluted to a target of 0.5 mg/mL using 5 mM succinate/0.9% saline, and then sterile filtered into FBC containers in a Class 100 hood.
  • the conjugate was stored at 2-8° C.
  • S. pneumoniae serotypes 4, 6B, 9V, 18C, 19F and 23F were obtained from Dr. Gerald Schiffman, State University of New York, Brooklyn, N.Y.
  • S. pneumoniae serotype 14 was obtained from the ATCC, strain 6314.
  • one vial of each of the desired serotypes of Streptococcus pneumoniae was used to start a fermentation batch.
  • Two bottles containing a soy-based medium and phenol red were adjusted to a pH range of 7.4 ⁇ 0.2 using sodium carbonate, and the required volume of 50% dextrose/1% magnesium sulfate solution was then added to the bottles.
  • the two bottles were inoculated with different amounts of seed.
  • the bottles were incubated at 36° ⁇ 2° C. until the medium turned yellow. Following incubation, samples were removed from each bottle and tested for optical density (OD) (0.3 to 0.9) and pH (4.6 to 5.5). One of the two bottles was selected for inoculation of the seed fermentor.
  • OD optical density
  • Soy-based medium was transferred to the seed fermentor and sterilized. Then a volume of 50% dextrose/1% magnesium sulfate solution was added to the fermentor. The pH and agitation of the seed fermentor were monitored and controlled (pH 6.7 to 7.4). The temperature was maintained at 36° ⁇ 2° C. The seed inoculum (bottle) was aseptically connected to the seed fermentor and the inoculum was transferred. The fermentor was maintained in pH control and samples were periodically removed and tested for OD and pH. When the desired OD of 0.5 at 600 nm was reached, the intermediate fermentor was inoculated with the fermentation broth from the seed fermentor.
  • Soy-based medium was transferred to the intermediate fermentor and sterilized. Then a volume of 50% dextrose/1% magnesium sulfate solution was added to the fermentor. The pH and agitation of the intermediate fermentor were monitored and controlled (pH 6.7 to 7.4). The temperature was maintained at 36° ⁇ 2° C. The contents of the seed fermentor were transferred to the intermediate fermentor. The fermentor was maintained in pH control and samples were periodically removed and tested for OD and pH. When the desired OD of 0.5 at 600 nm was reached, the production fermentor was inoculated with the fermentation broth from the intermediate fermentor.
  • Soy-based medium was transferred to the production fermentor and sterilized. Then a volume of 50% dextrose/1% magnesium sulfate solution was added to the fermentor. The pH and agitation of the production fermentor were monitored and controlled (pH 6.7 to 7.4). The temperature was maintained at 36° ⁇ 2° C. The fermentor was maintained in pH control and samples were periodically removed and tested for OD and pH, until the fermentation was complete.
  • Deoxycholate sodium was added to the fermentor to a final concentration of approximately 0.12% w/v.
  • the culture was mixed for a minimum of thirty minutes and the temperature set point was reduced to 10° C.
  • the culture was incubated overnight and following confirmation of inactivation, the pH of the culture was adjusted to between 6.4 and 6.8, as necessary, with 50% acetic acid.
  • the temperature of the fermentor was increased to 20° ⁇ 5° C. and the contents were transferred to the clarification hold tank.
  • the contents of the clarification hold tank (including the cellular debris) were processed through a centrifuge at a flow rate between 25 and 600 liters per hour (except Serotype 4, wherein the cell debris was discarded and the flow rate tightened to between 25 and 250 liters per hour). Samples of the supernatant were removed and tested for OD. The desired OD during the centrifugation was ⁇ 0.15.
  • the supernatant was recirculated through a depth filter assembly until an OD of 0.05 ⁇ 0.03 was achieved. Then the supernatant was passed through the depth filter assembly and through a 0.45 ⁇ m membrane filter to the filtrate hold tank.
  • each pneumococcal polysaccharide consisted of several concentration/diafiltration operations, precipitation/elution, column chromatography, and depth filtration steps. All procedures were performed at room temperature unless otherwise specified.
  • Clarified broth from the fermentor cultures of the desired S. pneumoniae serotype was concentrated and diafiltered using a 100 kDa MWCO filter. Diafiltration was accomplished using sodium phosphate buffer at pH ⁇ 9.0. Diafiltration removed the low molecular weight medium components from the higher molecular weight biopolymers such as nucleic acid, protein and polysaccharide.
  • the polysaccharide was precipitated from the concentrated and diafiltered solution by adding HB from a stock solution to give a final concentration of 1% HB (w/v) (except Serotype 23F, which had a final concentration of 2.5%).
  • the polysaccharide/HB precipitate was captured on a depth filter and the filtrate was discarded. (Note: Serotype 14 does not precipitate; therefore the filtrate was retained.)
  • the polysaccharide precipitate was resolubilized and eluted by recirculating a sodium chloride solution through the precipitate-containing depth filter. The filters were then rinsed with additional sodium chloride solution.
  • NaI sodium iodide
  • the precipitate was removed by depth filtration.
  • the filtrate contained the target polysaccharide.
  • the filter was discarded.
  • the polysaccharide was then filtered through a 0.2 ⁇ m filter.
  • the polysaccharide solution was concentrated on a 30 kDa MWCO ultrafilter and diafiltered with a sodium chloride solution.
  • the partially purified polysaccharide solution was further purified by filtration through a depth filter impregnated with activated carbon. After filtration, the carbon filter was rinsed with a sodium chloride solution. The rinse was combined with the polysaccharide solution, which was then filtered through a 0.2 ⁇ m filter.
  • the polysaccharide solution was concentrated on a 30 kDa MWCO ultrafilter and the filter was rinsed with a sodium chloride solution. The pH was checked and adjusted to 7.0 ⁇ 0.3.
  • the ceramic hydroxyapatite (HA) column was equilibrated with sodium phosphate buffer containing sodium chloride until the pH is 7.0 ⁇ 0.3 and the conductivity was 26 ⁇ 4 ⁇ S.
  • the polysaccharide solution was then loaded onto the column. Under these conditions, impurities bound to the resin and the polysaccharide was recovered in the flow through from the column.
  • the polysaccharide solution was filtered through a 0.2 ⁇ m filter.
  • the polysaccharide solution was concentrated using a 30 kDa MWCO filter. The concentrate was then diafiltered with WFI until the conductivity was ⁇ 15 ⁇ S.
  • the diafiltered polysaccharide solution was filtered through a 0.2 ⁇ m membrane filter into bulk containers and stored at 2-8° C.
  • the different serotype saccharides follow different pathways for activation (hydrolysis or no hydrolysis prior to activation) and conjugation (aqueous or DMSO reactions) as described in this example.
  • Polysaccharide was transferred from the bulk containers to the reactor vessel. The polysaccharide was then diluted in WFI and sodium phosphate to a final concentration range of 1.6-2.4 mg/mL.
  • pH was adjusted to pH 6.0 ⁇ 0.3.
  • the required sodium periodate molar equivalents for pneumococcal saccharide activation was determined using total saccharide content (except for serotype 4). For serotype 4, a ratio of 0.8-1.2 moles of sodium periodate per mole of saccharide was used. With thorough mixing, the oxidation reaction was allowed to proceed between 16 to 20 hours at 21-25° C. for all serotypes except 19F for which the temperature was ⁇ 15° C.
  • the oxidized saccharide was concentrated and diafiltered with WFI (0.01 M sodium phosphate buffer pH 6.0 for serotype 19F) on a 100 kDa MWCO ultrafilter (5 kDa ultrafilter for 18C). The permeate was discarded and the retentate was filtered through a 0.22 ⁇ m filter.
  • the concentrated saccharide was mixed with CRM 197 carrier protein, filled into glass bottles, shell-frozen and stored at ⁇ 65° C.
  • the frozen concentrated saccharide-CRM 197 was lyophilized and then stored at ⁇ 25° ⁇ 5° C.
  • the lyophilized activated saccharide-CRM 197 mixture was thawed and equilibrated at room temperature.
  • the lyophilized activated saccharide-CRM 197 was then reconstituted in 0.1M sodium phosphate buffer at a typical ratio of:
  • the reaction mixture was incubated at 37° ⁇ 2° C. until total dissolution for the serotype 9V and at 23° ⁇ 2° C. for serotypes 4 and 14.
  • the lyophilized saccharide was reconstituted in a solution of CRM 197 in 1M dibasic sodium phosphate at a typical ratio of 0.11 L of sodium phosphate per 1 L of CRM 197 solution.
  • the reaction mixture (8-12 g/L saccharide concentration) was incubated at 23° ⁇ 2° C. until total dissolution.
  • the pH was tested as an in-process control at this stage.
  • the conjugation reaction was initiated by adding the sodium cyanoborohydride solution (100 mg/mL) to achieve 1.0-1.4 moles sodium cyanoborohydride per mole of saccharide.
  • the reaction mixture was incubated for 44-52 hours at 37° ⁇ 2° C. The temperature was then reduced to 23° ⁇ 2° C. and sodium chloride 0.9% was added to the reactor.
  • Sodium borohydride solution (100 mg/mL) was added to achieve 1.8-2.2 molar equivalents of sodium borohydride per mole saccharide.
  • the mixture was incubated for 3-6 hours at 23° ⁇ 2° C.
  • the mixture was diluted with sodium chloride 0.9% and the reactor was rinsed.
  • the diluted conjugation mixture was filtered using a 1.2 ⁇ m pre-filter into a holding vessel.
  • the conjugation reaction was initiated by adding the cyanoborohydride solution (100 mg/mL) to achieve 1.0-1.4 moles of sodium cyanoborohydride per mole of saccharide.
  • the reaction mixture was incubated for 12-24 hours at 23° ⁇ 2° C. The temperature was increased to 37° ⁇ 2° C. and the reaction was incubated for 72-96 hours. The temperature was then reduced to 23° ⁇ 2° C. and 0.9% sodium chloride was added to the reactor.
  • Sodium borohydride solution (100 mg/mL) was added to achieve 1.8-2.2 molar equivalents of sodium borohydride per mole of saccharide.
  • the mixture was incubated for 3-6 hours at 23° ⁇ 2° C.
  • the mixture was diluted with 0.9% sodium chloride and the reactor was rinsed.
  • the diluted conjugation mixture was then filtered using a 1.2 ⁇ m pre-filter into a holding vessel.
  • Step 3 Ultrafiltration 100 kDa
  • the diluted conjugation mixture was concentrated and diafiltrated on a 100 kDa MWCO ultrafilter with either a minimum of 15 volumes (serotype 4) or 40 volumes (serotypes 9V, 14, and 18C) of 0.9% sodium chloride.
  • the retentate was filtered through a 0.45 ⁇ m filter.
  • This step was only performed for the serotype 4 conjugate.
  • the HA column was first neutralized using 0.5M sodium phosphate buffer (pH 7.0 ⁇ 0.3) and then equilibrated with 0.9% sodium chloride.
  • the filtered retentate (serotype 4) was loaded onto the column at a flow rate of 1.0 L/min.
  • the column was washed with 0.9% sodium chloride at a flow rate of ⁇ 2.0 L/min.
  • the product was then eluted with 0.5M sodium phosphate buffer at a flow rate of ⁇ 2.0 L/min.
  • the HA fraction was then concentrated and diafiltered on a 100 kDa MWCO membrane with a minimum of 20 volumes of 0.9% sodium chloride. The permeate was discarded.
  • Step 5 Sterile Filtration
  • the retentate after the 100 kDa MWCO diafiltration was filtered through a 0.22 ⁇ m filter.
  • In-process controls saccharide content, free protein, free saccharide and cyanide
  • In-process controls on filtered retentate were performed to determine whether additional concentration, diafiltration, and/or dilution were needed to meet FBC targets. These and additional tests were repeated in FBC samples.
  • the filtered conjugate was diluted with 0.9% sodium chloride in order to achieve a final concentration of less than 0.55 g/L. Release tests for saccharide content, protein content and saccharide:protein ratio were performed at this stage.
  • the conjugate was filtered (0.22 ⁇ m) and filled into 10 L stainless steel canisters at a typical quantity of 2.64 g/canister.
  • yield saccharide content, protein content, pH, saccharide:protein ratio and lysine content were performed as in-process controls.
  • Release testing (appearance, free protein, free saccharide, endotoxin, molecular size determination, residual cyanide, saccharide identity, CRM 197 identity) was performed at this stage.
  • the lyophilized activated saccharide serotypes 6B, 19F, 23F and the lyophilized CRM 197 carrier protein were equilibrated at room temperature and reconstituted in DMSO.
  • the dissolution concentration typically ranged from 2-3 grams of saccharide (2-2.5 g protein) per liter of DMSO.
  • the activated saccharide and CRM 197 carrier protein were mixed for 60-75 minutes at 23° ⁇ 2° C. at a ratio range of 0.6 g-1.0 g saccharide/g CRM 197 for serotypes 6B and 19F or 1.2 to 1.8 g saccharide/g CRM 197 for serotype 23F.
  • the conjugation reaction was initiated by adding the sodium cyanoborohydride solution (100 mg/mL) at a ratio of 0.8-1.2 molar equivalents of sodium cyanoborohydride to one mole activated saccharide. WFI was added to the reaction mixture to a target of 1% (v/v) and the mixture was incubated for over 40 hours at 23° ⁇ 2° C.
  • Step III 100 kDa Ultrafiltration
  • the diluted conjugate mixture was filtered through a 1.2 ⁇ m filter and concentrated and diafiltered on a 100 kDa MWCO membrane with a minimum of 15 volumes of 0.9% sodium chloride (0.01M sodium phosphate/0.05M NaCl buffer was used for serotype 23F). The permeate was discarded. The retentate was filtered through a 0.45 ⁇ m filter. An in-process saccharide content sample was taken at this stage.
  • This step was only performed for serotype 23F.
  • the DEAE column was equilibrated with 0.01M sodium phosphate/0.05M sodium chloride buffer.
  • the filtered retentate (serotype 23F) was loaded onto the column and washed with 0.01M sodium phosphate/0.05M sodium chloride buffer.
  • the column was then washed with 0.01M sodium phosphate/0.9% NaCl buffer.
  • the product was then eluted with 0.01M sodium phosphate/0.5M sodium chloride buffer.
  • Step V 100 kDa Ultrafiltration
  • the retentate from 6B and 19F was concentrated and diafiltered with at least 30 volumes of 0.9% sodium chloride. The permeate was discarded.
  • the eluate from serotype 23F was concentrated and diafiltered with a minimum of 20 volumes of 0.9% sodium chloride. The permeate was discarded.
  • Step VI Sterile Filtration
  • the retentate after the 100 kDa MWCO diafiltration was filtered through 0.22 ⁇ m filter.
  • In-process controls saccharide content, free protein, free saccharide, residual DMSO and residual cyanide
  • In-process controls on filtered retentate were performed to determine whether additional concentration, diafiltration, and/or dilution were needed to meet FBC targets. These and additional tests were repeated in FBC samples.
  • the filtered conjugate was diluted with 0.9% sodium chloride to achieve a final concentration of less than 0.55 g/L. Release tests for saccharide content, protein content and saccharide:protein ratio were performed at this stage.
  • the conjugate was filtered (0.22 ⁇ m) and filled into 10 L stainless steel canisters at a quantity of 2.64 g/canister.
  • yield saccharide content, protein content, pH, saccharide:protein ratio and lysine content were performed as in-process controls.
  • Release testing (appearance, free protein, free saccharide, endotoxin, molecular size determination, residual cyanide, residual DMSO, saccharide identity and CRM 197 identity) was performed at this stage.
  • the final bulk concentrates of the 13 conjugates contain 0.85% sodium chloride.
  • Type 3, 6A, 7F and 19A bulk concentrates also contain 5 mM sodium succinate buffer at pH 5.8.
  • the required volumes of bulk concentrates were calculated based on the batch volume and the bulk saccharide concentrations.
  • the preparation was then sterile filtered through a 0.22 ⁇ m membrane into a second container by using a Millipore Durapore membrane filter unit.
  • the first container was washed with the remaining 20% of 0.85% sodium chloride and the solution was passed through the same filter and collected into the second container.
  • the formulated bulk was mixed gently during and following the addition of bulk aluminum phosphate.
  • the pH was checked and adjusted if necessary.
  • the formulated bulk product was stored at 2-8° C.
  • the formulated bulk product was filled into Type 1 borosilicate glass syringes obtained from Becton Dickinson.
  • the vaccine was monitored at regular intervals for turbidity to ensure the uniformity of the filling operation.
  • the filled vaccine (Final Product) was stored at 2-8° C.
  • Study #HT01-0021 examined the ability of the 13vPnC vaccine with AIPO 4 adjuvant to elicit vaccine serotype-specific immune responses.
  • the pneumococcal serotypes represented in the 13vPnC vaccine include types 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.
  • New Zealand White rabbits were immunized intramuscularly at week 0 and week 2 with the planned human clinical dose of each polysaccharide (2 ⁇ g of each PS, except 4 ⁇ g of 6B) formulated with or without AIPO 4 (100 ⁇ g/dose).
  • Sera were collected at various time points.
  • Serotype specific IgG was measured by ELISA and functional activity was assessed by OPA.
  • Table 3 shows the geometric mean titer (GMT) achieved in pooled serum samples, following two doses of the 13vPnC vaccine.
  • GTT geometric mean titer
  • the kinetic responses to each of the 13vPnC vaccine serotypes were evaluated from serum pools of both treatment groups. IgG titers to each serotype were measured from blood draws at week 0 and weeks 1, 2, 3, 4, 8, 12, 26, and 39 and then compared. With the exception of serotype 1, antibody responses in animals receiving adjuvanted vaccine were superior to those that received non-adjuvanted vaccine and peaked at week 2 of the immunization schedule (data not shown).
  • Study #HT01-0036 compared rabbit immune responses to the polysaccharides (PSs) contained in the vaccine, after immunization with the 13vPnC vaccine with or without conjugation to the CRM 197 protein.
  • New Zealand White rabbits were immunized intramuscularly at week 0 and week 2 with a dose of 2.2 ⁇ g of each PS (except 4.4 ⁇ g of 6B).
  • Animals received one of three vaccine preparations: (a) 13vPnC (PS directly conjugated to CRM 197 ), (b) 13vPnPS, (free PS) or (c) 13vPnPS+CRM 197 (free PS mixed with CRM 197 ). All vaccine preparations contained AIPO 4 as the adjuvant at 125 ⁇ g/dose.
  • Serotype specific immune responses for all vaccine preparations were evaluated in an IgG ELISA and complement-mediated OPA measuring functional antibody. The immune responses were compared between the treatment groups.
  • Table 5 presents GMT data obtained from week 4 bleeds analyzed in antigen specific IgG ELISAs. Additional analyses show the ratio of GMT values at week 4 to week 0. The data indicate that the conjugate vaccine preparation elicited greater serum IgG titers than free PS or free PS+CRM 197 vaccine.
  • the 13vPnC vaccine was able to induce functional antibodies to the representative strains of S. pneumoniae in an OPA (Table 6). After two immunizations with either the 13vPnPS or 13vPnPS+CRM 197 vaccine, neither could induce OPA titers ⁇ 8-fold at week 4 relative to week 0 for 10 out of the 13 serotypes measured (Table 6).
  • Containers of purified polysaccharide were thawed and combined in a reaction vessel.
  • 30 mM sodium bicarbonate/carbonate buffer, pH 9.0 was added for partial de-O-acetylation (hydrolysis) for 3 hours at 50° C.
  • De-O-acetylation to approximately 40 mole percent was performed.
  • the reaction was cooled to 20° C. and neutralization was performed by 0.2 M acetic acid to a pH of 5.0-7.0. Partial oxidation in the presence of sodium periodate was performed by incubation at 2-8° C., and the mixture was stirred for 15-21 hours.
  • the reaction mixture was purified by diafiltration against 10 ⁇ volumes of 0.9% saline using a 30K MWCO regenerated cellulose membrane.
  • the purified, activated polysaccharide was compounded with CRM 197 at a polysaccharide/protein ratio of 2:1, shell-frozen at ⁇ 75° C. and co-lyophilized. Following co-lyophilization, the polysaccharide/CRM 197 mixture was stored at ⁇ 25° ⁇ 5° C. until conjugation.
  • To the co-lyophilized polysaccharide/CRM 197 mixture 1 M sodium phosphate buffer was added to a final 0.2M ionic strength and a pH of 7.5, then sodium cyanoborohydride was added. The reaction was incubated at 23° C.
  • reaction mixture was diluted with cold saline followed by the addition of 1 M sodium carbonate to adjust the reaction mixture to pH 9.0. Unreacted aldehydes were quenched by addition of sodium borohydride by incubation at 23° C. for 3-6 hours.
  • the reaction mixture was diluted 2-fold with saline and transferred through a 0.45-5 ⁇ m prefilter into a retentate vessel, then diafiltered 30 ⁇ with 0.15 M phosphate buffer, pH 6.0, and 20 ⁇ with saline.
  • the retentate was filtered through a 0.2 ⁇ m filter.
  • the conjugate solution was diluted to a target of 0.5 mg/mL in 0.9% saline, and then sterile filtered into final bulk concentrate containers in a Class 100 hood.
  • the conjugate was stored at 2-8° C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
US11/644,207 2005-04-08 2006-12-22 Multivalent pneumococcal polysaccharide-protein conjugate composition Abandoned US20070184072A1 (en)

Priority Applications (29)

Application Number Priority Date Filing Date Title
US11/644,207 US20070184072A1 (en) 2005-04-08 2006-12-22 Multivalent pneumococcal polysaccharide-protein conjugate composition
CA2673558A CA2673558C (en) 2006-12-22 2007-12-10 Multivalent pneumococcal polysaccharide-protein conjugate composition
CN201510490666.4A CN105079800A (zh) 2006-12-22 2007-12-10 多价肺炎球菌多糖-蛋白缀合物组合物
KR1020147029398A KR20140130564A (ko) 2006-12-22 2007-12-10 다가 폐렴구균 다당류-단백질 접합체 조성물
SI200731710T SI2094304T1 (sl) 2006-12-22 2007-12-10 Večvalentni pnevmokokni konjugatni sestavek polisaharida in beljakovine
EP07865465.4A EP2094304B1 (en) 2006-12-22 2007-12-10 Multivalent pneumococcal polysaccharide-protein conjugate composition
KR1020097015487A KR101511393B1 (ko) 2006-12-22 2007-12-10 다가 폐렴구균 다당류-단백질 접합체 조성물
PT78654654T PT2094304E (pt) 2006-12-22 2007-12-10 Composição de conjugado polissacarídeo-proteína pneumocócica multivalente
RU2009123449/15A RU2484846C2 (ru) 2006-12-22 2007-12-10 Мультивалентная композиция на основе конъюгата пневмокковый полисахарид-белок
KR1020157031392A KR20150129052A (ko) 2006-12-22 2007-12-10 다가 폐렴구균 다당류-단백질 접합체 조성물
BRPI0721136A BRPI0721136B8 (pt) 2006-12-22 2007-12-10 método para produzir um conjugado imunogênico que compreende polissacarídeo de streptococcus pneumoniae sorotipo 1 encadeado de modo covalente a uma proteína de veículo
SG2011089216A SG177174A1 (en) 2006-12-22 2007-12-10 Multivalent pneumococcal polysaccharide-protein conjugate composition
PCT/US2007/086976 WO2008079653A1 (en) 2006-12-22 2007-12-10 Multivalent pneumococcal polysaccharide-protein conjugate composition
DK07865465.4T DK2094304T3 (en) 2006-12-22 2007-12-10 MULTIVALENT PNEUMOCOCPOLYSACCHARIDE PROTEIN CONJUGATE COMPOSITION
AU2007337214A AU2007337214B9 (en) 2006-12-22 2007-12-10 Multivalent pneumococcal polysaccharide-protein conjugate composition
HUE07865465A HUE028421T2 (en) 2006-12-22 2007-12-10 Multivalent pneumococcal polysaccharide-protein conjugate preparation
ES07865465.4T ES2559060T3 (es) 2006-12-22 2007-12-10 Composición de un conjugado multivalente de polisacárido neumocócico-proteína
CNA2007800515966A CN101610788A (zh) 2006-12-22 2007-12-10 多价肺炎球菌多糖-蛋白缀合物组合物
PL07865465T PL2094304T3 (pl) 2006-12-22 2007-12-10 Multiwalentna kompozycja koniugatu pneumokokowego polisacharydu i białka
MX2009006548A MX336934B (es) 2006-12-22 2007-12-10 Composicion conjugada polisacarido-proteina neumococica multivalente.
JP2009543058A JP5815207B2 (ja) 2006-12-22 2007-12-10 多価肺炎球菌多糖−タンパク質コンジュゲート組成物
CL2007003781A CL2007003781A1 (es) 2006-12-22 2007-12-21 Metodo para la elaboracion de un conjugado inmunogenico que comprende el polisacarido del serotipo 1 de streptococcus pneumoniae covalentemente unido a una proteina vehiculo; y proceso para preparar una composicion inmunogenica multivalente polisacarido-proteina.
US12/471,113 US20090234108A1 (en) 2005-04-08 2009-05-22 Multivalent pneumococcal polysaccharide-protein conjugate composition
IL199324A IL199324A (en) 2006-12-22 2009-06-11 METHOD FOR PREPARING AN IMMUNITIVE BACKGROUND CONTAINING SUGAR TYPE 1 STRAPTOCOCCUS CELLENTALLY CONCENTRATED TO CARRIER PROTEIN
ZA200904619A ZA200904619B (en) 2006-12-22 2009-07-01 Multivalent pneumococcal polysaccharide-protein conjugate composition
US12/887,636 US8895724B2 (en) 2005-04-08 2010-09-22 Multivalent pneumococcal polysaccharide-protein conjugate composition
JP2013241484A JP2014065721A (ja) 2006-12-22 2013-11-22 多価肺炎球菌多糖−タンパク質コンジュゲート組成物
US14/520,108 US9480736B2 (en) 2005-04-08 2014-10-21 Multivalent pneumococcal polysaccharide-protein conjugate composition
HK16103260.9A HK1215189A1 (zh) 2006-12-22 2016-03-21 多價肺炎球菌多糖-蛋白綴合物組合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66960505P 2005-04-08 2005-04-08
US11/395,593 US20060228380A1 (en) 2005-04-08 2006-03-31 Multivalent pneumococcal polysaccharide-protein conjugate composition
US11/644,207 US20070184072A1 (en) 2005-04-08 2006-12-22 Multivalent pneumococcal polysaccharide-protein conjugate composition

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/395,593 Continuation-In-Part US20060228380A1 (en) 2005-04-08 2006-03-31 Multivalent pneumococcal polysaccharide-protein conjugate composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/471,113 Continuation US20090234108A1 (en) 2005-04-08 2009-05-22 Multivalent pneumococcal polysaccharide-protein conjugate composition

Publications (1)

Publication Number Publication Date
US20070184072A1 true US20070184072A1 (en) 2007-08-09

Family

ID=39386416

Family Applications (4)

Application Number Title Priority Date Filing Date
US11/644,207 Abandoned US20070184072A1 (en) 2005-04-08 2006-12-22 Multivalent pneumococcal polysaccharide-protein conjugate composition
US12/471,113 Abandoned US20090234108A1 (en) 2005-04-08 2009-05-22 Multivalent pneumococcal polysaccharide-protein conjugate composition
US12/887,636 Active 2029-04-04 US8895724B2 (en) 2005-04-08 2010-09-22 Multivalent pneumococcal polysaccharide-protein conjugate composition
US14/520,108 Active US9480736B2 (en) 2005-04-08 2014-10-21 Multivalent pneumococcal polysaccharide-protein conjugate composition

Family Applications After (3)

Application Number Title Priority Date Filing Date
US12/471,113 Abandoned US20090234108A1 (en) 2005-04-08 2009-05-22 Multivalent pneumococcal polysaccharide-protein conjugate composition
US12/887,636 Active 2029-04-04 US8895724B2 (en) 2005-04-08 2010-09-22 Multivalent pneumococcal polysaccharide-protein conjugate composition
US14/520,108 Active US9480736B2 (en) 2005-04-08 2014-10-21 Multivalent pneumococcal polysaccharide-protein conjugate composition

Country Status (22)

Country Link
US (4) US20070184072A1 (pt)
EP (1) EP2094304B1 (pt)
JP (2) JP5815207B2 (pt)
KR (3) KR20150129052A (pt)
CN (2) CN101610788A (pt)
AU (1) AU2007337214B9 (pt)
BR (1) BRPI0721136B8 (pt)
CA (1) CA2673558C (pt)
CL (1) CL2007003781A1 (pt)
DK (1) DK2094304T3 (pt)
ES (1) ES2559060T3 (pt)
HK (1) HK1215189A1 (pt)
HU (1) HUE028421T2 (pt)
IL (1) IL199324A (pt)
MX (1) MX336934B (pt)
PL (1) PL2094304T3 (pt)
PT (1) PT2094304E (pt)
RU (1) RU2484846C2 (pt)
SG (1) SG177174A1 (pt)
SI (1) SI2094304T1 (pt)
WO (1) WO2008079653A1 (pt)
ZA (1) ZA200904619B (pt)

Cited By (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010067202A2 (en) 2008-12-11 2010-06-17 Novartis Ag Mixing lyophilised meningococcal vaccines with non-hib vaccines
US20100160622A1 (en) * 2008-12-18 2010-06-24 Wyeth Llc Method for controlling streptococcus pneumoniae polysaccharide molecular weight using carbon dioxide
US20100158953A1 (en) * 2008-12-18 2010-06-24 Wyeth Llc Method for controlling streptococcus pneumoniae serotype 19a polysaccharide molecular weight
WO2010109323A1 (en) 2009-03-24 2010-09-30 Novartis Ag Adjuvanting meningococcal factor h binding protein
WO2010125480A1 (en) 2009-04-30 2010-11-04 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
WO2011161653A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
US20120189654A1 (en) * 2006-04-07 2012-07-26 Glaxosmithkline Biologicals, S.A. Vaccine
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
US20120321660A1 (en) * 2010-03-09 2012-12-20 Ralph Leon Biemans Conjugation process of bacterial polysaccharides to carrier proteins
WO2013098589A1 (en) 2011-12-29 2013-07-04 Novartis Ag Adjuvanted combinations of meningococcal factor h binding proteins
WO2013132043A1 (en) 2012-03-08 2013-09-12 Novartis Ag Combination vaccines with tlr4 agonists
WO2013131983A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
WO2014037472A1 (en) 2012-09-06 2014-03-13 Novartis Ag Combination vaccines with serogroup b meningococcus and d/t/p
WO2014095771A1 (en) 2012-12-18 2014-06-26 Novartis Ag Conjugates for protecting against diphtheria and/or tetanus
WO2015110940A2 (en) 2014-01-21 2015-07-30 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
WO2015110942A2 (en) 2014-01-21 2015-07-30 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
WO2015110941A2 (en) 2014-01-21 2015-07-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015144031A1 (zh) * 2014-03-26 2015-10-01 天津康希诺生物技术有限公司 一种肺炎球菌多糖蛋白缀合疫苗及其制备方法
EP3017826A1 (en) 2009-03-24 2016-05-11 Novartis AG Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
EP2932979A4 (en) * 2012-12-11 2016-06-01 Sk Chemicals Co Ltd COMPOSITION OF A POLYSACCHARIDE-MULTIVALENT PNEUMOCOCCAL PROTEIN CONJUGATE
WO2016113644A1 (en) 2015-01-15 2016-07-21 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
WO2016178123A1 (en) 2015-05-04 2016-11-10 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
WO2017013548A1 (en) 2015-07-21 2017-01-26 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
WO2017085586A1 (en) 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
WO2017216286A1 (en) 2016-06-17 2017-12-21 Glaxosmithkline Biologicals S.A. Immunogenic composition
US9884113B2 (en) 2005-12-22 2018-02-06 Glaxosmithkline Biologicals, Sa Pneumoccal polysacchride conjugate vaccine
WO2018027123A1 (en) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2018027126A1 (en) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2018087635A1 (en) 2016-11-09 2018-05-17 Pfizer Inc. Immunogenic polysaccharide protein conjugated comprising a polysaccharide derived from b streptococcus gbs
WO2018126229A2 (en) 2016-12-30 2018-07-05 Sutrovax, Inc. Polypeptide-antigen conjugates with non-natural amino acids
WO2018134693A1 (en) 2017-01-20 2018-07-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US10034949B2 (en) 2012-06-20 2018-07-31 Sk Chemicals Co., Ltd. Polyvalent pneumococcal polysaccharide-protein conjugate composition
WO2019050815A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER
WO2019139692A2 (en) 2017-12-06 2019-07-18 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
WO2020009993A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Improvements in immunogenic conjugates
WO2020010016A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Self-adjuvanted immunogenic conjugates
WO2020010000A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Improved methods for the preparation of immunogenic conjugates
WO2020039359A2 (en) 2018-08-24 2020-02-27 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2020120569A2 (en) 2018-12-12 2020-06-18 Glaxosmithkline Biologicals Sa Modified carrier proteins for o-linked glycosylation
WO2020121159A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
US10688170B2 (en) 2017-06-10 2020-06-23 Inventprise, Llc Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity
WO2020131763A2 (en) 2018-12-19 2020-06-25 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
WO2020208502A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP3757217A1 (en) 2019-06-27 2020-12-30 GlaxoSmithKline Biologicals S.A. Methods for protein purification
WO2021021729A1 (en) 2019-07-31 2021-02-04 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
EP3789494A1 (en) * 2019-09-06 2021-03-10 Serum Institute of India Private Limited Method for obtaining purified bacterial polysaccharides
WO2021084429A1 (en) 2019-11-01 2021-05-06 Pfizer Inc. Escherichia coli compositions and methods thereof
US11090375B2 (en) * 2014-01-21 2021-08-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2021165928A2 (en) 2020-02-23 2021-08-26 Pfizer Inc. Escherichia coli compositions and methods thereof
EP3900739A1 (en) 2020-04-21 2021-10-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein
EP3919076A1 (en) 2020-06-02 2021-12-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic oligosaccharide vaccines against streptococcus pneumoniae with microparticle adjuvant formulations
WO2021259742A1 (en) 2020-06-25 2021-12-30 Glaxosmithkline Biologicals Sa Modified exotoxin a proteins
WO2022043855A1 (en) 2020-08-26 2022-03-03 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
WO2022090893A2 (en) 2020-10-27 2022-05-05 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2022097010A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
WO2022137078A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2022234405A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
WO2022249106A2 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2022249107A2 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023118033A1 (en) 2021-12-22 2023-06-29 Glaxosmithkline Biologicals Sa Vaccine
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110839A2 (en) 2022-11-22 2024-05-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
TWI445545B (zh) 2005-04-08 2014-07-21 Wyeth Corp 多價肺炎球菌多醣-蛋白質共軛物組合物
KR20130122810A (ko) * 2005-06-27 2013-11-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
EP3626263A1 (en) 2010-06-04 2020-03-25 Wyeth LLC Vaccine formulations
GB201218660D0 (en) 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
CN116870144A (zh) 2017-01-31 2023-10-13 默沙东有限责任公司 制备多糖-蛋白缀合物的方法
KR20240011879A (ko) 2017-02-24 2024-01-26 머크 샤프 앤드 돔 엘엘씨 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체의 면역원성의 증진
AU2018328038B2 (en) 2017-09-07 2024-03-07 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
CN111093649B (zh) 2017-09-07 2023-08-25 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
JOP20200214A1 (ar) 2019-09-03 2021-03-03 Serum Institute Of India Pvt Ltd تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها
EP4243863A2 (en) 2020-11-10 2023-09-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR102610292B1 (ko) * 2021-02-10 2023-12-04 에스케이바이오사이언스(주) 스트랩토코커스 뉴모니애 다당류와 운반체 단백질의 접합체 제조 방법
WO2023192997A2 (en) * 2022-03-31 2023-10-05 The Children's Medical Center Corporation Immunogenic compositions for b-cell recall response to a polysaccharide antigen
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US5306492A (en) * 1990-09-28 1994-04-26 American Cyanamid Company Oligosaccharide conjugate vaccines
US20010048929A1 (en) * 1998-02-23 2001-12-06 Pele Chong Novel multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US20060165730A1 (en) * 2002-05-09 2006-07-27 Massimo Porro Polysaccharide and glycoconjugate vaccines
US20060228380A1 (en) * 2005-04-08 2006-10-12 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070231340A1 (en) * 2005-04-08 2007-10-04 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4097666A (en) * 1976-04-29 1978-06-27 The Institute Of Paper Chemistry Solvent system for polysaccharides
US5097020A (en) * 1983-07-05 1992-03-17 The University Of Rochester Immunogenic conjugates
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
CA2245588C (en) * 1996-02-14 2006-05-09 Russel J. Lander Polysaccharide precipitation process
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
MXPA01003073A (es) 1998-09-24 2002-04-24 Univ Minnesota Polipeptido que degrada la proteina c3 complementaria humana a partir de streptococcus pneumoniae.
EP1035137A1 (en) 1999-03-12 2000-09-13 Pasteur Merieux Serums Et Vaccins Method for the reductive amination of polysaccharides
AR022963A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Biolog Vacuna
EA006313B1 (ru) * 2000-06-29 2005-10-27 Глаксосмитклайн Байолоджикалс С.А. Поливалентные иммуногенные композиции и способы их применения
WO2002048029A1 (en) * 2000-12-13 2002-06-20 Sca Hygiene Products Zeist B.V. Recovery process for spent periodate
GB0130215D0 (en) 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
AU2003257003A1 (en) 2002-07-30 2004-02-16 Baxter Healthcare S.A. Chimeric multivalent polysaccharide conjugate vaccines
WO2004026024A2 (en) * 2002-09-20 2004-04-01 The United States Of America As Represented By The Secretary Of Agriculture Vaccine compositions and adjuvant
FR2850106B1 (fr) 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
BRPI0413309B8 (pt) * 2003-08-06 2021-05-25 The Government Of The Us Secretary Department Of Health And Human Services método para a preparação de uma vacina conjugada de polissacarídeo-proteína
ATE460498T1 (de) * 2003-09-11 2010-03-15 Staat Der Nederlanden Vert Doo Verfahren zur herstellung eines kapselpolysaccharids zur verwendung in konjugat- impfstoffen
FR2857364B1 (fr) 2003-12-08 2005-09-23 Aventis Pasteur Dosage des acides techoiques des bacteries gram+
WO2005058940A2 (en) * 2003-12-17 2005-06-30 Wyeth Immunogenic peptide carrier conjugates and methods of producing same
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US5306492A (en) * 1990-09-28 1994-04-26 American Cyanamid Company Oligosaccharide conjugate vaccines
US20010048929A1 (en) * 1998-02-23 2001-12-06 Pele Chong Novel multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US20060165730A1 (en) * 2002-05-09 2006-07-27 Massimo Porro Polysaccharide and glycoconjugate vaccines
US20060228380A1 (en) * 2005-04-08 2006-10-12 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070231340A1 (en) * 2005-04-08 2007-10-04 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition

Cited By (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10646564B2 (en) 2005-12-22 2020-05-12 Glaxosmithkline Biologicals S.A. Vaccine
US10279033B2 (en) 2005-12-22 2019-05-07 Glaxosmithkline Biologicals Sa Vaccine comprising Streptococcus pneumoniae capsular polysaccharide conjugates
US9884113B2 (en) 2005-12-22 2018-02-06 Glaxosmithkline Biologicals, Sa Pneumoccal polysacchride conjugate vaccine
US11400147B2 (en) 2005-12-22 2022-08-02 Glaxosmithkline Biologicals Sa Pneumococcal capsular saccharide conjugate vaccine
US20120189654A1 (en) * 2006-04-07 2012-07-26 Glaxosmithkline Biologicals, S.A. Vaccine
WO2010067202A2 (en) 2008-12-11 2010-06-17 Novartis Ag Mixing lyophilised meningococcal vaccines with non-hib vaccines
WO2010080486A2 (en) 2008-12-18 2010-07-15 Wyeth Llc Method for controlling streptococcus pneumoniae serotype 19a polysaccharide molecular weight
WO2010080484A1 (en) 2008-12-18 2010-07-15 Wyeth Llc Method for controlling streptococcus pneumoniae polysaccharide molecular weight using carbon
US20100158953A1 (en) * 2008-12-18 2010-06-24 Wyeth Llc Method for controlling streptococcus pneumoniae serotype 19a polysaccharide molecular weight
US11376315B2 (en) 2008-12-18 2022-07-05 Wyeth Llc Method for controlling Streptococcus pneumoniae polysaccharide molecular weight using carbon dioxide
US20100160622A1 (en) * 2008-12-18 2010-06-24 Wyeth Llc Method for controlling streptococcus pneumoniae polysaccharide molecular weight using carbon dioxide
US8795689B2 (en) 2008-12-18 2014-08-05 Wyeth Llc Method for controlling Streptococcus pneumoniae serotype 19A polysaccharide molecular weight
WO2010109323A1 (en) 2009-03-24 2010-09-30 Novartis Ag Adjuvanting meningococcal factor h binding protein
EP3017826A1 (en) 2009-03-24 2016-05-11 Novartis AG Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
WO2010125480A1 (en) 2009-04-30 2010-11-04 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
US9205143B2 (en) 2009-04-30 2015-12-08 Coley Pharmaceutical Group Inc. Pneumococcal vaccine and uses thereof
US8753645B2 (en) * 2010-03-09 2014-06-17 Glaxosmithkline Biologicals S.A. Conjugation process of bacterial polysaccharides to carrier proteins
EP2815762A2 (en) 2010-03-09 2014-12-24 GlaxoSmithKline Biologicals S.A. Conjugation process of bacterial polysaccharides to carrier proteins
US20120321660A1 (en) * 2010-03-09 2012-12-20 Ralph Leon Biemans Conjugation process of bacterial polysaccharides to carrier proteins
EP2815762B1 (en) 2010-03-09 2017-05-31 GlaxoSmithKline Biologicals S.A. Conjugation process of bacterial polysaccharides to carrier proteins
US9265840B2 (en) 2010-03-09 2016-02-23 Glaxosmithkline Biologicals S.A. Conjugation process of bacterial polysaccharides to carrier proteins
US9265839B2 (en) 2010-03-09 2016-02-23 Glaxosmithkline Biologicals S.A. Conjugation process of bacterial polysaccharides to carrier proteins
WO2011161653A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
US10596246B2 (en) 2011-12-29 2020-03-24 Glaxosmithkline Biological Sa Adjuvanted combinations of meningococcal factor H binding proteins
WO2013098589A1 (en) 2011-12-29 2013-07-04 Novartis Ag Adjuvanted combinations of meningococcal factor h binding proteins
WO2013131983A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
WO2013132043A1 (en) 2012-03-08 2013-09-12 Novartis Ag Combination vaccines with tlr4 agonists
US10058607B2 (en) 2012-06-20 2018-08-28 Sk Chemicals Co., Ltd. Polyvalent pneumococcal polysaccharide-protein conjugate composition
US10034949B2 (en) 2012-06-20 2018-07-31 Sk Chemicals Co., Ltd. Polyvalent pneumococcal polysaccharide-protein conjugate composition
WO2014037472A1 (en) 2012-09-06 2014-03-13 Novartis Ag Combination vaccines with serogroup b meningococcus and d/t/p
US9526776B2 (en) 2012-09-06 2016-12-27 Glaxosmithkline Biologicals Sa Combination vaccines with serogroup B meningococcus and D/T/P
US9981029B2 (en) 2012-12-11 2018-05-29 Sk Chemical Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
EP2932979A4 (en) * 2012-12-11 2016-06-01 Sk Chemicals Co Ltd COMPOSITION OF A POLYSACCHARIDE-MULTIVALENT PNEUMOCOCCAL PROTEIN CONJUGATE
WO2014095771A1 (en) 2012-12-18 2014-06-26 Novartis Ag Conjugates for protecting against diphtheria and/or tetanus
US11426456B2 (en) 2014-01-21 2022-08-30 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
US11872274B2 (en) 2014-01-21 2024-01-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015110941A2 (en) 2014-01-21 2015-07-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3957321A2 (en) 2014-01-21 2022-02-23 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
EP4286000A2 (en) 2014-01-21 2023-12-06 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
EP3607966A1 (en) 2014-01-21 2020-02-12 Pfizer Inc Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US11090375B2 (en) * 2014-01-21 2021-08-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US10105431B2 (en) * 2014-01-21 2018-10-23 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
WO2015110940A2 (en) 2014-01-21 2015-07-30 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US10918708B2 (en) * 2014-01-21 2021-02-16 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
US9492559B2 (en) 2014-01-21 2016-11-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20190000953A1 (en) * 2014-01-21 2019-01-03 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
WO2015110942A2 (en) 2014-01-21 2015-07-30 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
EP3616716A2 (en) 2014-01-21 2020-03-04 Pfizer Inc Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3583947A1 (en) 2014-01-21 2019-12-25 Pfizer Inc Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
WO2015144031A1 (zh) * 2014-03-26 2015-10-01 天津康希诺生物技术有限公司 一种肺炎球菌多糖蛋白缀合疫苗及其制备方法
WO2016113644A1 (en) 2015-01-15 2016-07-21 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US10653764B2 (en) 2015-01-15 2020-05-19 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US11135279B2 (en) 2015-01-15 2021-10-05 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US10946086B2 (en) 2015-05-04 2021-03-16 Pfizer Inc. Group B Streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
WO2016178123A1 (en) 2015-05-04 2016-11-10 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
US10226525B2 (en) 2015-05-04 2019-03-12 Pfizer Inc. Group B Streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
US11020469B2 (en) 2015-07-21 2021-06-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
WO2017013548A1 (en) 2015-07-21 2017-01-26 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
US10124050B2 (en) 2015-07-21 2018-11-13 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
US10786561B2 (en) 2015-11-20 2020-09-29 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
WO2017085586A1 (en) 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
WO2017216286A1 (en) 2016-06-17 2017-12-21 Glaxosmithkline Biologicals S.A. Immunogenic composition
WO2018027123A1 (en) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2018027126A1 (en) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
US12016913B2 (en) 2016-11-09 2024-06-25 Pfizer Inc. Immunogenic compositions and uses thereof
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
WO2018087635A1 (en) 2016-11-09 2018-05-17 Pfizer Inc. Immunogenic polysaccharide protein conjugated comprising a polysaccharide derived from b streptococcus gbs
US11147865B2 (en) 2016-11-09 2021-10-19 Pfizer Inc. Immunogenic compositions and uses thereof
US11998599B2 (en) 2016-12-30 2024-06-04 Vaxcyte, Inc. Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
WO2018126229A2 (en) 2016-12-30 2018-07-05 Sutrovax, Inc. Polypeptide-antigen conjugates with non-natural amino acids
WO2018134693A1 (en) 2017-01-20 2018-07-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US11413344B2 (en) 2017-01-20 2022-08-16 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US10688170B2 (en) 2017-06-10 2020-06-23 Inventprise, Llc Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
US11376323B2 (en) 2017-06-10 2022-07-05 Inventprise, Llc Mixtures of polysaccharide protein pegylated compounds
WO2019050815A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER
US11116828B2 (en) 2017-12-06 2021-09-14 Merck Sharp & Dohme Corp. Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
US11850278B2 (en) 2017-12-06 2023-12-26 Merck Sharp & Dohme Llc Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
WO2019139692A2 (en) 2017-12-06 2019-07-18 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
WO2020009993A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Improvements in immunogenic conjugates
WO2020010016A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Self-adjuvanted immunogenic conjugates
WO2020010000A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Improved methods for the preparation of immunogenic conjugates
WO2020039359A2 (en) 2018-08-24 2020-02-27 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2020121159A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
WO2020120569A2 (en) 2018-12-12 2020-06-18 Glaxosmithkline Biologicals Sa Modified carrier proteins for o-linked glycosylation
US11642406B2 (en) 2018-12-19 2023-05-09 Merck Sharp & Dohme Llc Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
US12016914B2 (en) 2018-12-19 2024-06-25 Merck Sharp & Dohme Llc Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
WO2020131763A2 (en) 2018-12-19 2020-06-25 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
WO2020208502A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP3757217A1 (en) 2019-06-27 2020-12-30 GlaxoSmithKline Biologicals S.A. Methods for protein purification
WO2021021729A1 (en) 2019-07-31 2021-02-04 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
WO2021028402A1 (en) 2019-08-15 2021-02-18 Glaxosmithkline Biologicals Sa Immunogenic composition
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
EP3789494A1 (en) * 2019-09-06 2021-03-10 Serum Institute of India Private Limited Method for obtaining purified bacterial polysaccharides
WO2021084429A1 (en) 2019-11-01 2021-05-06 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2021165928A2 (en) 2020-02-23 2021-08-26 Pfizer Inc. Escherichia coli compositions and methods thereof
EP3900739A1 (en) 2020-04-21 2021-10-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein
WO2021214179A2 (en) 2020-04-21 2021-10-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein
EP3919076A1 (en) 2020-06-02 2021-12-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic oligosaccharide vaccines against streptococcus pneumoniae with microparticle adjuvant formulations
WO2021244996A1 (en) 2020-06-02 2021-12-09 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic oligosaccharide vaccines against streptococcus pneumoniae with microparticle adjuvant formulations
WO2021259742A1 (en) 2020-06-25 2021-12-30 Glaxosmithkline Biologicals Sa Modified exotoxin a proteins
WO2022043855A1 (en) 2020-08-26 2022-03-03 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
WO2022090893A2 (en) 2020-10-27 2022-05-05 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2022097010A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
WO2022137078A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2022234405A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
WO2022249107A2 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2022249106A2 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023118033A1 (en) 2021-12-22 2023-06-29 Glaxosmithkline Biologicals Sa Vaccine
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
WO2024110839A2 (en) 2022-11-22 2024-05-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations

Also Published As

Publication number Publication date
AU2007337214A1 (en) 2008-07-03
CN105079800A (zh) 2015-11-25
CL2007003781A1 (es) 2009-01-23
JP2010513550A (ja) 2010-04-30
BRPI0721136A2 (pt) 2014-04-01
HK1215189A1 (zh) 2016-08-19
US20110071279A1 (en) 2011-03-24
AU2007337214B2 (en) 2013-05-16
MX336934B (es) 2016-02-08
CA2673558C (en) 2016-11-15
US20150038685A1 (en) 2015-02-05
CN101610788A (zh) 2009-12-23
BRPI0721136A8 (pt) 2019-01-29
HUE028421T2 (en) 2016-12-28
SG177174A1 (en) 2012-01-30
DK2094304T3 (en) 2016-01-25
PT2094304E (pt) 2016-02-15
BRPI0721136B8 (pt) 2021-05-25
SI2094304T1 (sl) 2016-01-29
ZA200904619B (en) 2010-07-28
JP2014065721A (ja) 2014-04-17
JP5815207B2 (ja) 2015-11-17
US20090234108A1 (en) 2009-09-17
PL2094304T3 (pl) 2016-04-29
AU2007337214B9 (en) 2013-10-31
RU2009123449A (ru) 2011-01-27
RU2484846C2 (ru) 2013-06-20
EP2094304B1 (en) 2015-11-18
KR20140130564A (ko) 2014-11-10
MX2009006548A (es) 2009-06-26
IL199324A (en) 2013-10-31
KR20150129052A (ko) 2015-11-18
ES2559060T3 (es) 2016-02-10
CA2673558A1 (en) 2008-07-03
US8895724B2 (en) 2014-11-25
WO2008079653A1 (en) 2008-07-03
US9480736B2 (en) 2016-11-01
BRPI0721136B1 (pt) 2019-06-18
KR20090094164A (ko) 2009-09-03
EP2094304A1 (en) 2009-09-02
KR101511393B1 (ko) 2015-04-13

Similar Documents

Publication Publication Date Title
US10716848B2 (en) Process for preparing pneumococcal polysaccharide-protein conjugates
US11969474B2 (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
US9480736B2 (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
US8603484B2 (en) Multivalent pneumococcal polysaccharide-protein conjugate composition

Legal Events

Date Code Title Description
AS Assignment

Owner name: WYETH, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HAUSDORFF, WILLIAM P.;SIBER, GEORGE RAINER;PARADISO, PETER R.;AND OTHERS;REEL/FRAME:019195/0904;SIGNING DATES FROM 20070318 TO 20070416

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: WYETH LLC, NEW JERSEY

Free format text: CHANGE OF NAME;ASSIGNOR:WYETH;REEL/FRAME:025224/0985

Effective date: 20091109